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Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated primarily from endogenous biochemical reactions
in mitochondria, endoplasmic reticulum (ER), and peroxisomes. Typically, ROS/RNS correlate with oxidative damage and cell
death; however, free radicals are also crucial for normal cellular functions, including supporting neuronal homeostasis.
ROS/RNS levels influence and are influenced by antioxidant systems, including the catabolic autophagy pathways. Autophagy is
an intracellular lysosomal degradation process by which invasive, damaged, or redundant cytoplasmic components, including
microorganisms and defunct organelles, are removed to maintain cellular homeostasis. This process is particularly important in
neurons that are required to cope with prolonged and sustained operational stress. Consequently, autophagy is a primary line of
protection against neurodegenerative diseases. Parkinson’s is caused by the loss of midbrain dopaminergic neurons (mDANs),
resulting in progressive disruption of the nigrostriatal pathway, leading to motor, behavioural, and cognitive impairments.
Mitochondrial dysfunction, with associated increases in oxidative stress, and declining proteostasis control, are key contributors
during mDAN demise in Parkinson’s. In this review, we analyse the crosstalk between autophagy and redoxtasis, including the
molecular mechanisms involved and the detrimental effect of an imbalance in the pathogenesis of Parkinson’s.
1. Introduction: Autophagy Forms, Roles,
and Regulation
Eukaryotic cells employ a variety of catabolic pathways to
degrade altered/damaged proteins and redundant macromo-
lecular components (e.g., organelles). These pathways are
critical for cellular homeostasis, and alterations in any have
been linked to diverse human diseases [1–4]. Autophagy is
one of the major catabolic quality control mechanisms, and
is adapted for the degradation of soluble as well as large
and/or insoluble cytosolic material, such as aggregated pro-
teins and damaged organelles [1, 2, 5, 6]. It describes several
distinct recycling pathways in which cytosolic cargoes are
removed through lysosomal degradation, releasing macro-
molecular precursors such as amino acids, lipids, and nucle-
osides back to the cytoplasm to be reused. As expected for a
process that contributes to removal of toxic cytosolic compo-
nents, autophagy dysregulation has been linked to numerous
diseases, including cancer, bone diseases, cardiomyopathy,
infectious diseases, metabolic disorders, and neurodegenera-
tive diseases [7–14]. In this review, we explore the roles of
one form of autophagy—macroautophagy—as a prominent
pathway for the removal of toxic protein aggregates and
damaged organelles, focusing on the interplay between
macroautophagy and redox homeostasis, and how imbal-
ances contribute to neuronal decline in Parkinson’s.
There are three types of autophagy, each with a distinct
mechanism for delivery of substrates to the lysosome. These
are microautophagy, chaperone-mediated autophagy
(CMA), and macroautophagy. In microautophagy, the cargo
is directly engulfed into lysosomes through lysosomal invag-
inations or protrusions [15]. CMA is a highly selective type of
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autophagy, where cargoes containing KFERQ-like motifs
and/or proteins that have been posttranslationally modified
(either by acetylation or phosphorylation) to generate
KFERQ-like motifs—becoming de novo CMA substrates
[16–18]—are selectively targeted via heat shock cognate
71 kDa protein (HSC70) and cochaperones, and internalized
to the lysosome lumen through the lysosome-associated
membrane protein 2 receptor (LAMP2A) for their degrada-
tion [18]. Thus, CMA plays an important role in the degrada-
tion of altered and aggregated proteins, and impairments in
this process have been linked to numerous diseases, includ-
ing neurodegenerative diseases. For example, accumulation
of CMA substrates such as α-synuclein (α-syn) and tau are
hallmarks, respectively, of Parkinson’s and tauopathies [19].
1.1. (Macro)autophagy. Macroautophagy is the best under-
stood of the three autophagy forms. It is commonly referred
to simply as “autophagy,” and we will adopt the same
nomenclature herein. Defects in autophagy are common
hallmarks of human diseases, including neurodegenerative
diseases [7]. During autophagy, cargoes are sequestered by
double-membrane vesicles called autophagosomes, which
eventually fuse with lysosomes to generate hybrid degrada-
tive compartments (the autolysosomes) (Figure 1) [7, 20–
23]. Autophagy is a highly conserved pathway in all eukary-
otes, and was first described in detail ~50 years ago by Chris-
tian De Duve; however, it was not until the early 1990s that
the Nobel Laureate Yoshinori Ohsumi began to unpick the
genetic and molecular basis of this process, including identi-
fying the proteins involved and their regulatory interplay
using budding yeast [24–26]. Since then, there has been a
remarkable progress in this field regarding the molecular
control of autophagy and its physiological relevance in
multicellular eukaryotes.
Although autophagy occurs in cells under basal condi-
tions, it is dramatically upregulated in response to stresses
including starvation, oxidative stress, and pathogen infection
[27]. Crucially, autophagy can be nonselective (also known as
cargo-independent autophagy), when portions of cytoplasm
are randomly encapsulated into autophagosomes based on
locality alone, or it can be highly selective. Here, autophagy
cargo receptors recognise and bind both cargo and the
autophagy machinery, thereby removing specific cargoes
such as protein aggregates or damaged organelles [28–31].
Thus, the machineries involved in selective and nonselective
autophagy are not identical (e.g., the requirement for specific
adaptors and cargo receptors) [32]. In selective autophagy,
contributing effector proteins differ depending on specific
cargoes, with the process being named according to the
organelle affected: mitophagy (mitochondria); pexophagy
(peroxisomes); ribophagy (ribosomes); reticulophagy (ER-
phagy); lysophagy (lysosomes); xenophagy (bacteria or virus;
being distinct from LC3-associated phagocytosis (LAP),
where LC3 (see below) is recruited directly to the single-
membrane phagosome [33]); nucleophagy (nucleus); protea-
phagy (proteasome); lipophagy (lipid droplets); ferritino-
phagy (ferritin); and glycophagy (glycogen) [28, 34].
Selective autophagy is also implicated in, e.g., noncanonical
secretion [35, 36], and LAP for the degradation of bacteria
or dead cells [37]. Relevant to a range of human diseases,
autophagy also selectively degrades aggregated/misfolded
proteins, by a process referred to as aggrephagy [38]. Aggre-
gated proteins that are common hallmarks of neurodegener-
ative diseases, and known autophagy substrates, include
amyloid-β [39, 40], that forms amyloid plaques in Alzhei-
mer’s disease; HTT (huntingtin) [41], the causative agent in
Huntington’s disease; and α-syn [42], a major component
of Lewy’s bodies associated with Parkinson’s and Lewy’s
body dementia. Befitting such an important process, a dedi-
cated family of protein is required for autophagy (with the
majority designated as “AuTophaGy-related” or “ATG” pro-
teins), and their functions are tightly regulated (a summary
of the proteins involved, and their functions, can be found
in Table 1) [7, 20–23, 43].
1.2. Mechanisms and Regulation of Autophagosome
Biogenesis: Initiation and Phagophore Expansion. The pro-
cess of autophagy consists of several sequential steps: (i) initi-
ation and nucleation; (ii) elongation; (iii) maturation; and (iv)
fusion with the endolysosomal compartment. In mammalian
cells, autophagy initiation involves the recruitment of several
complexes to the autophagy initiation sites and the formation
of the phagophore (also known as the isolation membrane).
Upon autophagy induction (e.g., nutrient starvation condi-
tions), the Unc51-like kinase 1 (ULK1) complex—formed by
the catalytic subunit ULK1, the regulatory subunit ATG13,
ATG101, and focal adhesion kinase family interacting protein
of 200kDa (FIP200)—is activated [44]. ULK1 activation
depends on its phosphorylation status: (i) it is inactivated by
the mammalian target or rapamycin Complex 1 (mTORC1),
which also inhibits ATG13 via phosphorylation; and (ii) it is
activated by adenosine monophosphate-activated protein
kinase (AMPK), which also inhibits mTORC1 directly by
phosphorylation, and indirectly via activation of tuberous scle-
rosis Complex 2 (TSC2) which controls the GTPase activity of
the Ras homolog enriched in brain (Rheb) (i.e., Rheb-GDP
inhibits mTORC1 activity). The latter process is inhibited in
autophagy-inducing conditions [45]. Once activated, ULK1
phosphorylates itself and other ULK1 complex components
(i.e., ATG13, FIP200, and ATG101), a step considered impor-
tant for the catalytic activity of the complex [46–48]. The
ULK1 complex is then recruited to the site of autophagosome
formation, generally in close-proximity to the endoplasmic
reticulum (ER)—or at ER-mitochondria contact sites—trig-
gering nucleation of the phagophore [7, 49–51]. The ULK1
complex activates the downstream machinery including via
(i) trafficking of ATG9-positive vesicles from the plasma
membrane, recycling endosomes, and trans-Golgi network
(TGN) to the autophagy initiation site [52–55]; and (ii)
activation by phosphorylation of the autophagic phos-
phatidylinositol 3-kinase class III Complex 1 (PI3KC3-C1;
also known as vacuolar protein sorting 34 Complex 1
(VPS34-I)). This complex comprises (i) the adaptor protein
VPS15; (ii) the catalytic subunit VPS34; (iii) ATG14L—re-
quired for ER targeting via interaction with syntaxin 17
(STX17) [56]; and (iv) the regulatory subunit coiled-coil
myosin-like BCL-2-interacting protein (BECLIN1; itself influ-
enced by AMBRA1 (activating molecule in BECLIN1-
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regulated autophagy [57])). When active, it establishes phos-
phatidylinositol 3-phosphate- (PI3P-) enriched subdomains
of the ER, known as omegasomes, from where phagophores
emerge [49, 58–60].
At the omegasome, PI3P effector proteins are recruited,
including the zinc-finger FYVE domain-containing protein
(DFCP1), the autophagy-linked FYVE protein (ALFY), and
WD repeat domain phosphoinositide-interacting proteins
(WIPIs; here WIPI2 is the exemplar isoform) [7]. DFCP1
resides on ER/Golgi membranes, and is an excellent omega-
some marker, but is thought not to be essential for autophagy
[58]. ALFY has been reported to be essential for selective deg-
radation of aggregated proteins, and is required for neuronal
connectivity [61, 62]. WIPI2 plays an important role in the
recruitment and activation of the tandemUb-like (UBL) con-
jugation pathways that drive autophagosome assembly,
namely, the ATG12 and the ATG8 conjugation systems
[43, 63, 64]. In the first UBL conjugation system, the UBL
protein ATG12 is conjugated to ATG5 by a process mediated
by ATG7 (E1-like activating enzyme) and ATG10 (E2-like
conjugating enzyme). ATG12~5 binds to ATG16L1, generat-
ing a complex with E3-like activity for the second UBL con-
jugation pathway [65, 66]. ATG12~5-16L1 complex
recruitment is mediated by direct interactions between
WIPI2B (WIPI2 splice variant) and ATG16L1 [63]. There,
the AT12~5-16L1 complex, together with ATG3 (E2-like
conjugating enzyme) and ATG7, coordinates activities in
the second UBL conjugation pathway, during which ATG8
family members are covalently attached to lipids (most often
to phosphatidyl ethanolamine (PE)) in situ. The ATG8
family comprises the microtubule associated protein 1 light
chain 3 (MAPLC3; herein, referred to as LC3) and gamma-
aminobutyric acid receptor-associated protein (GABARAP)
families. These families encompass LC3A (with two variants
differing in the N-terminal sequence, v1 and v2 [67]), LC3B
(LC3B1 and LC3B2, with only one amino acid difference
(C113 versus Y113 [67]), LC3C, GABARAP, GABARAPL1,
GABARAPL2/GATE-16 [68]. Prior to lipidation, ATG8s
are first activated (or primed) by members of the ATG4
endopeptidase family (ATG4A-D; with ATG4B being the
best characterised family member which displays activity
against all ATG8s), which cleave ATG8 proteins at their C-
termini to expose a glycine residue (e.g., G120 in LC3B) that
is the future site for lipidation (e.g., primed LC3 is referred to
as “LC3-I”) [7, 22, 69]. The subsequent covalent attachment
of ATG8s to lipids at the nascent isolation membrane gener-
ates the membrane-bound form (e.g., LC3-II) [70, 71], a step
that is followed by coordinating membrane expansion and
phagophore closure.
1.3. Mechanisms and Regulation of Autophagosome
Biogenesis: Maturation, Trafficking, and Lysosomal Fusion.
Autophagosome maturation and fusion with lysosomes
involves (i) membrane fission for autophagosome closure;
(ii) trafficking of the autophagosome along the cytoskele-
ton, typically in the retrograde direction (i.e., towards the
centre of a typical cell); and finally (iii), fusion with the
lysosome to form a degradative autolysosome [43]. Here,
cargoes are degraded, and their components transported


































































































































































Figure 1: Redox regulation of autophagy. Free radicals in the cell are mainly generated in mitochondria, peroxisomes, and ER; thus, a tightly
regulated process to ensure proper functionality and turnover is crucial for cell survival (i.e., degradation by selective autophagy, e.g.,
mitophagy (i) or pexophagy (ii)). Under certain conditions (e.g., oxidative damage), autophagy is induced as an antioxidant pathway, and
this leads to the initiation and nucleation of autophagy assembly sites (e.g., at the ER), with subsequent formation of the autophagosome,
and eventual fusion with a lysosome to form a degradative autolysosome. ROS/RNS have the potential to regulate autophagy via upstream
regulators, including proteins involved in the UPR system and the autophagy inhibitor mTOR, as well as redox modification in the
cytoskeleton, affecting autophagosome transport. In addition, direct modifications in proteins involved in the autophagy process have also
been identified including those involved in ATG8 cleavage and conjugation (i.e., ATG4 involved in LC3 cleavage; ATG3 and ATG7
involved in ATG8 lipidation), PI3KC3 activation and cargo recognition (e.g., p62/SQSTM1), and in selective autophagy (e.g., ATM in
pexophagy and PINK1, Parkin and DJ-1 for mitophagy) (see the text for full description). Finally, autophagy and redoxtasis crosstalk is
evident at the transcriptional level, with several transcription factors involved in autophagy regulation subject to redox modification. Some
transcription factors regulate both redox levels and the autophagy process (e.g., NRF2, FOXOs, and p53). P (green): highlights
phosphorylation events; Ub (black): highlights ubiquitination events; Ox (red): highlights sites for redox regulation of autophagy.
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complex required for transport) have been identified as
essential for autophagosome membrane fission/closure.
These are recruited in a RAS-related protein 5- (RAB5-)
dependent manner [72]. Defects in LC3B lipidation have
been found to cause the accumulation of unclosed
autophagosomes, suggesting that the ATG-conjugation
machinery is needed for this process [73]. Despite this,
functional autophagosomes do form in the absence of all
ATG8 family members [74]. Other interventions that lead
to the accumulation of unsealed autophagosomes in the
cytoplasm include knockdown of the phospholipid transfer
protein ATG2A/B, required for autophagosome expansion
[75]. Indeed, it was recently shown that an ATG2-
GABARAP interaction is needed for efficient autophago-
some closure [76].
Fully formed autophagosomes go through a maturation
process during which ATG8 proteins link autophagosomes
to motor proteins and the microtubule cytoskeleton. For
example, RAB7 is recruited to mature autophagosomes and
further recruits the FYVE and coiled-coil domain-
containing 1 protein (FYCO1), which in turn binds to LC3
(via LIR- (LC3-interacting region-) type interaction) and
PI3P to mediate anterograde kinesin-driven transport [77].
Alternatively, RAB7 binds to the RAB-interacting lysosomal
protein (RILP) to mediate retrograde dynactin/dynein-
driven transport towards the nucleus [78–82]. Crucially,
microtubules are also involved in autophagosome formation
(e.g., microtubule transport from the centrosome is necessary
for recruitment of GABARAP to the nascent phagophore via
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For membrane fusion and formation of the autolysosome,
the SNARE (soluble N-ethylmaleimide-sensitive factor
activating protein receptor) fusion machinery is required. On
the autophagosome membrane resides STX17 and
synaptosomal-associated protein 29 (SNAP29), whereas on
the lysosome, vesicle-associated membrane protein 7 or 8
(VAMP7 or VAMP8) mediates membrane fusion supported
by the homotypic fusion and protein sorting complex (HOPS)
which interacts with STX17 [84, 85]. STX17 also recruits
ATG14L (also involved in autophagosome formation as a
complex of PI3KC3-C1) to promote membrane tethering
and to stabilise the SNARE complex promoting membrane
fusion [86–88]. In addition, Wilkinson et al. described that
phosphorylation of LC3B by hippo kinases STK3 and STK4
was critical for autophagosome fusion [89]. Meanwhile Wang
et al. described that ULK1mediates autophagosome-lysosome
fusion via interactions with STX17, with protein kinase α-
(PKCα-) mediated ULK1 phosphorylation reducing this
interaction via ULK1 degradation by the CMA pathway [90].
1.4. General Features and Properties of Autophagy in
Neurons. Autophagy pathways in general are especially
important in neurons, as these are postmitotic cells that can-
not dilute cytoplasmic damage through proliferation/divi-
sion, and thus autophagy is required to maintain long-term
neuronal functionality. Although this review focuses on
(macro)autophagy, it is important to mention that CMA
andmicroautophagy are also present in neurons [91]. In neu-
rons, autophagy is needed to degrade neurotoxic factors (e.g.,
α-syn) and damaged organelles that are selected by ubiquity-
lation and recognised by the autophagy machinery [92, 93].
Misfolded proteins can be refolded by the actions of
chaperones, or can be degraded primarily by the ubiquitin-
proteasome system (UPS); however, when these processes
are impaired, misfolded proteins accumulate to form aggre-
gates (aggresomes) that require removal via aggrephagy
[94], otherwise insoluble inclusions are generated [95, 96].
These are defining features of some neurodegenerative
diseases, including Parkinson’s [2]. In autophagy-deficient
dopaminergic neurons (mDANs), derived from Atg7 knock-
out mice, α-syn and p62/SQSTM1 both accumulate in inclu-
sions within neurites in an ageing-dependent fashion that is
ultimately linked to mDAN loss and motor dysfunction [96].
Autophagy also contributes to axonal regeneration, pre-
synaptic modelling, dendritic spine pruning, and synaptic
plasticity [91, 97–100]. Autophagy dysregulation has been
linked to the development of neurodegenerative diseases
[101–103], and crucially, decreased autophagic activity is a
characteristic of ageing [8]. Autophagy supports neuronal
survival. For example, neonatal lethality in Atg5 knockout
mice is rescued after restoration of neuronal-specific expres-
sion of ATG5 [104]; meanwhile, autophagy activation in the
mouse brain protects against mDAN loss mediated by oxida-
tive stress [105], and autophagy induction using a neuronal
pharmacophore in amyotrophic lateral sclerosis (ALS) and
Huntington’s mouse models promotes neuronal survival
[106]. Consistent with this, suppression of basal autophagy
also causes neurodegeneration. For example, conditional
neuronal autophagy deficiency leads to neuronal loss, and
mutations in autophagy genes have been linked to several
neurodegenerative disorders [103, 107–109].
Previous work in primary rodent neurons points to
unique characteristics of autophagosome assembly, matura-
tion, and trafficking in these specialised cells [97, 110].
Importantly, control and substrate targeting appear to differ
depending on neuronal cell-type and specific conditions.
For example, in neurons of the dorsal root ganglia (DRG),
autophagy is triggered almost exclusively at the distal tip,
whereas in hippocampal primary neurons, it can be initiated
in the cell body, dendrites, and axonal regions proximal to
the cell body [111, 112]. However, under stress conditions,
mitophagy initiation has been reported to also occur along
the axon [113]. In general, autophagosome biogenesis is ini-
tiated primarily in the distal axon, and thereafter, autophago-
somes undergo dynein-dependent retrograde motility to the
lysosome-rich soma following recruitment of neuronal scaf-
fold proteins such as JIP1 [112, 114]. Overall, it is essential
that neuronal subtype specification is considered when
attempting to generalise about the roles and regulation of
autophagy in the brain.
Autophagosome biogenesis is a constitutive process that
can be triggered in the soma or distal axon where elements
of the core autophagy machinery are actively recruited (e.g.,
ATG9A-containing vesicles are transported from the soma
to the distal axons via the kinesin family member, KIF1A
[115]). Supplementing these, several neuron-specific proteins
have been reported to be involved in autophagosome biogen-
esis and maturation (e.g., synaptojanin, endophilin A, Basson,
and Piccolo) (Table 1). The presynaptic proteins, endophilin
A and synaptojanin (mutations in SYNJ1 are associated with
Parkinson’s [116]), are primarily involved in the recycling of
synaptic vesicles [117], but have also been shown to mediate
ATG3 recruitment to the nascent phagophore [118] and to
promote autophagosome maturation [119], respectively. Bas-
son and Piccollo are two proteins involved in active zone
assembly for the release of neurotransmitters, and they have
each been found to act as autophagy inhibitors by sequestering
ATG5 [120]. Autophagosome biogenesis can also occur in
dendrites (or alternatively, autophagosomes can also migrate
from the soma to the dendrites), and here autophagy activity
increases as a function of synaptic activity [111, 121]. Further-
more, recent studies have suggested the existence of an uncon-
ventional degradation pathway in which glial cells modulate
neuronal autophagy by intercellular regulation and/or direct
transfer of cellular garbage from neurons, an idea that builds
on previous data supporting autophagosome secretion in
nonneuronal cells [97, 122].
Neuronal autophagy properties also appear to vary as a
function of ageing, with accumulation of neuromelanin and
lipofuscin progressively observed in autophagosomes in
aging brain tissues [123]. Overall, autophagosome biogenesis
efficiency is seen to decline in aged neurons [124].
2. Selective Autophagy and Its Relevance to
Neurodegenerative Diseases
As a key component of cellular and tissue homeostasis, with
protective roles in human neurodegenerative diseases, a full
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appreciation of mitophagy regulatory control in neurons is
desirable. In particular, mitophagy dysfunction is a hallmark
of Parkinson’s, implicated in a number of early onset genetic
forms [125], and is observed in genetic and toxin-induced
Parkinson’s models [126]. Distinct mechanisms and diverse
proteins are involved in the selective degradation of mito-
chondria, and these have been reviewed in detail elsewhere
[32, 103]. Mitochondria can be damaged by numerous fac-
tors, including hypoxia, mtDNA damage, chemical uncou-
plers that dissipate membrane potential (e.g., carbonyl
cyanide m-chlorophenylhydrazone (CCCP)), electron trans-
port complex (ETC) inhibitors (e.g., rotenone (Complex I
inhibitor) or antimycin (Complex III inhibitor)), or the pres-
ence of reactive oxygen species (ROS; mitochondrial super-
oxide production), as will be described in detail later [127–
129]. Thereafter, differing fates are observed, with damaged
mitochondria either being rescued by fusion/fission [130]
or being degraded via mitophagy.
2.1. The PINK1/Parkin Mitophagy Pathway. The best charac-
terised route for mitochondrial degradation is via the
PINK1/Parkin (PRKN) pathway, although several Parkin-
independent pathways have been described [131–135]. Cru-
cially, PINK1 and PRKNmutations are linked to familial Par-
kinson’s [9]. When mitochondrial membrane potential is
intact, PINK1 is imported into mitochondria via the TOM/-
TIM23 system (translocase of the outer membrane and inner
membrane, respectively), to be cleaved consecutively by the
matrix-localized protease (MPP) and presenilin-associated
rhomboid-like protease (PARL) [128, 136]. However, when
membrane potential is lost (i.e., as a feature of damagedmito-
chondria), PINK1 accumulates on the mitochondrial outer
membrane where it phosphorylates and activates Parkin
(an E3 ligase), driving protein ubiquitylation on the outer
mitochondrial membrane. Subsequently, PINK1 phosphory-
lates target-bound ubiquitin which in turn recruits further
Parkin in a positive feedback pathway [137]. Parkin targets
mitochondrial surface proteins, such as the voltage-
dependent anion channel 1 (VDAC1) [138]. For Parkin
recruitment and substrate ubiquitination, an interaction with
the Parkinson’s-linked protein F-box protein 7 (FBXO7) is
involved, although the precise molecular mechanism remains
elusive [139]. These ubiquitylated proteins are recognised by
cargo receptor proteins, and thereafter ubiquitylated
mitochondria are targeted to the nascent phagophore.
Zachari et al. suggested that ubiquitylated mitochondria are
enveloped by ER strands to facilitate targeting and autophagy
[140].
2.2. Cargo Receptors and Their Roles in Mitophagy,
Pexophagy, and ER-Phagy. There are several cargo receptor
proteins involved in mitophagy, including p62/SQSTM1,
NIX (or BNIPL3), Neurabin-1 (NRB1), FUNDC1 (FUN14-
domain-containing 1), NDP52, Optineurin (OPTN), and
Tax1 binding protein 1 (TAX1BP1) [127]. Recruitment of
these receptor proteins occurs subject to specific regulation.
For example, receptor binding affinity (particularly OPTN
and p62/SQSTM1) is increased via phosphorylation by tank-
binding kinase 1 (TBK1) [141, 142]. These receptors bind to
ATG8s (via LIR-type interactions) [55], and some of them also
recruit the ULK1 complex in a feed-forward pathway to rein-
force the autophagosome assembly machinery [143, 144].
Subsequently, mitochondria are degraded by the (macro)auto-
phagy pathway. Ubiquitin is not the only targeting signal for
mitophagy, as it has been recently described that the mito-
chondrial matrix proteins 4-nitrophenylphosphatase domain
and nonneuronal SNAP25-like protein homolog (NIPSNAP1)
and NIPSNAP2 accumulate on the mitochondrial surface to
act as “eat-me” signals through binding to mitophagy cargo
receptors [135]. In addition, it has been observed in neurons
that cardiolipin externalization on the mitochondrial surface
triggers mitophagy via interactions with LC3, thereby
targeting mitochondria for degradation [134, 145, 146].
Some cargo receptors involved in mitophagy—including
NDP52, OPTN, NRB1, and p62/SQSTM1—also facilitate the
degradation of protein aggregates (aggrephagy), or other
organelles such as peroxisomes (pexophagy) [147, 148]. Per-
oxisomes are small single-membrane organelles involved in
lipid synthesis and redox homeostasis. Thus, pexophagy is
crucial for peroxisome quality control and turnover [149]. In
this process, peroxisome membrane proteins, including the
peroxisomal biogenesis factor (PEX) 5 and 70kDa peroxi-
somal membrane protein (PMP70), are ubiquitylated by the
E3-like ubiquitin ligase complex PEX2-PEX10-PEX12, facili-
tating recognition by cargo receptors and degradation via
autophagy [149]. Alternatively, to prevent pexophagy, the
deubiquitinase USP30 and the AAA-type ATPase (PEX1-
PEX6-PEX26) remove ubiquitylated membrane proteins.
Conversely, peroxisomal dysfunction are linked to peroxisome
biogenesis disorders. However, the effect of altered pexophagy
in neurodegenerative diseases is poorly understood [150].
Other specific proteins implicated in the selective
autophagy of different organelles include the following LIR-
motif-containing proteins involved in ER-phagy: CCPG1
(cell cycle progression protein 1), FAM134B (family with
sequence similarity 134 member B); ATL3 (atlastin 3),
SEC62 (secretory 62 homolog), CALCOCO1 (calcium-bind-
ing and coiled-coil domain 1), RTN3 (reticulon 3), and
TEX264 (testis-expressed protein 264); they are found in dif-
ferent regions of the ER, and they might have different roles
and be tissue-specific [151–160]. The ER is a complex organ-
elle that mediates protein folding, processing and transport
in the secretory pathway, calcium storage, lipid synthesis,
and intracellular signalling via interactions with other organ-
elles. In common with other organelles, the ER is also subject
to turnover and remodelling to ensure proper and optimal
functional plasticity [161, 162]. The best characterised net-
work for ER remodelling is the unfolded protein response
(UPR), triggered by the presence of lumenal misfolded pro-
teins, with the consequent cytosolic signalling cascades orig-
inated by ER-sensing proteins: inositol-requiring enzyme 1α
(IRE1α), protein kinase RNA-like ER kinase (PERK), and
activating transcription factor 6 (ATF6). These cascades trig-
ger the translational and transcriptional regulation of redox
enzymes, chaperones, foldases, lipid synthesis proteins,
autophagy-related proteins (e.g., CCPG1 [152]), and ERAD
(ER-associated degradation) genes involved in proteasomal
degradation [163].
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Under nutrient starvation or ER stress (i.e., lumenal mis-
folded proteins), ER-phagy is induced via different pathways
after UPR activation. Calcium released via the inositol tris-
phosphate receptor IP3R and other calcium channels acti-
vates calcium-dependent proteins, namely, calmodulin-
dependent protein kinase (CAMKK), which inhibits
mTORC1 [164, 165]; death-associated kinase (DAPK) and
DAPK2 which regulate BECLIN1 activation andmTOR inhi-
bition, respectively, [166–168]; and CAMK2B, which phos-
phorylates FAM134B, promoting its oligomerization [169].
On the other hand, IRE1α indirectly activates BECLIN1, thus
promoting autophagy initiation, while PERK and ATF6,
respectively, activate two autophagy transcription factors,
ATF4 (activating transcription factor 4) and CHOP (C/EBP
homologous protein) [170, 171] (for a detailed overview,
see [172]). ER-phagy can be classified as macro-ER-phagy
(commonly referred as “ER-phagy”), where fragments of
ER are sequestered into an autophagosome which later fuses
with the lysosome, and micro-ER-phagy, when a fragment of
the ER is directly engulfed and targeted to the lysosome (for
recent reviews, see [173, 174]). Recently, numerous human
ER-phagy regulators have been identified in a genome-wide
screening after starvation [159], and recent data highlight
the importance of ER-phagy in cell survival, with defects in
this process being related to infectious diseases and cancer
development and progression (for a review, see [175]).
In neurons, the ER extends from the cell body and along
the axon to the axonal distal tip. It is crucial for neuronal
function (particularly the regulation of the neuronal calcium
homeostasis), and the ER tubular network is disrupted in sev-
eral neurodegenerative diseases [176–178]. Consistent with
this, UPR has been recently implicated in memory, synaptic
plasticity, dendritic outgrowth and branching, and axonal
regeneration [179–182]. In addition, previous studies have
highlighted the importance of ER-phagy in neurons. For
example, (i) FAM134B deficiency in primary neurons leads
to progressive ER stress and affects the survival of sensory
neurons [156]; (ii) RTN3 is linked to AD [183]; and most
recently, (iii) Park et al. described that induction of ER stress
and consequent ER-phagy is involved in early stages of
hypothalamic development and metabolic regulation [184].
However, the role of ER-phagy in neuronal homeostasis
and neurodegenerative diseases remain to be fully explored.
3. Redox Homeostasis
Reactive oxygen species (ROS) (e.g., hydrogen peroxide
(H2O2) and superoxide (O2
•-)) and reactive nitrogen species
(RNS) (e.g., nitric oxide (•NO)) are highly reactive molecules
generated under both basal and pathological or stress condi-
tions (for a detailed description of free radicals see [185]).
They are involved in numerous pathologies, including Par-
kinson’s, Alzheimer’s, ALS, diabetes, cancer, and autoim-
mune disorders [186]. These radicals are important for
cellular homeostasis, regulating several cellular functions
including cell signalling, proliferation, and survival in
response to stress or injury. Reduction and oxidation reac-
tions, where there is a transfer of electrons between chemical
species—also known as redox reactions—are focused at the
mitochondria, peroxisomes, and ER, although there are addi-
tional contributions from alternative organelles depending
on the cell type [187, 188]. In addition, cells have different
inherent antioxidant mechanisms to control ROS/RNS levels
and avoid/alleviate toxicity. Oxidative stress occurs when
antioxidant mechanisms are not sufficient, and ROS/RNS
levels accumulate, ultimately impacting on normal biological
processes and limiting cell survival. Due to the high oxygen
demands and lipid contents in the brain, neurons are partic-
ularly sensitive to oxidative stress, with some areas being
more susceptible than others (e.g., the hippocampus) [189].
For this reason, high levels of oxidative stress are one of the
main hallmarks of neurodegenerative diseases, including
Parkinson’s, aggravating the disorder by affecting protein
aggregation, DNA damage, and ultimately, causing neuronal
cell death.
3.1. Sources and Causes of Redox Imbalance. Mitochondria
are the major source of cellular ATP, generated via the elec-
tron transport chain (ETC), comprising (i) Complex I
(NADH dehydrogenase), which uses NADPH generated in
the citric acid cycle for proton translocation from the mito-
chondrial matrix to the intermembrane space, with electrons
being transferred to ubiquinone; (ii) Complex II (succinate
dehydrogenase), which uses flavin adenine dinucleotide
(FADH2) generated from succinate in the citric acid cycle
and consequently delivers electrons to the ETC (ubiquinone);
(iii) Complex III (cytochrome c oxidoreductase), where elec-
trons (from ubiquinone) are transferred to cytochrome c; (iv)
Complex IV (cytochrome c oxidase), where electrons are
removed from cytochrome c to generate H2O with energy
released used to translocate protons to the intermembrane
space; and (v) Complex V (ATP synthase), for the generation
of ATP via proton flow to the matrix (at a ratio of
4H+ : 1ATP) [190]. Complexes I, II, and III are among the
major ROS production enzymes in the cell, generating O2
•-
due to electron leakage [191]. In addition, glycerol-3-
phosphate dehydrogenase, which catalyses the conversion
of glycerol-3-phosphate to dihydroxyacetone phosphate
and the generation of FADH2 while transferring electrons
to ubiquinone in the ETC, generates additional O2
•-. Simi-
larly, also in the inner mitochondrial membrane, the electron
transfer to flavoprotein, ubiquinone oxidoreductase, and
dihydroorotate dehydrogenase, that, respectively, links fatty
acid β-oxidation and pyrimidine biosynthesis to electron
transfer to the ETC, also generates O2
•- [192]. The other
major source of ROS in mitochondria is the Krebs cycle (or
citric acid cycle). This metabolic pathway is performed by
aerobic organisms in the mitochondrial matrix, and consists
of a series of chemical reactions for the production of ATP,
alongside reduced forms of NADH and FADH2 to be used
in the ETC. Particularly, dihydrolipoamide dehydrogenase
(DLD), an E3 component of pyruvate dehydrogenase (for
the production of acetyl-CoA from pyruvate), and α-ketoglu-
tarate dehydrogenase (catalyses the conversion of α-ketoglu-
tarate to succinyl-CoA, producing NADH), generates
unwanted O2
•- via the flavin cofactor of this enzyme. Finally,
superoxide dismutase 2 (SOD2) in the mitochondrial matrix,
and SOD1 in the intermembrane space, convert O2
•- into
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H2O2, which can potentially be turned into
•OH radicals via
the Fenton reaction. Mitochondria are also sources of RNS,
including •NO that is produced by nitric oxide synthases
(NOS) in the oxidation of L-arginine [188, 193]. Peroxisomes
are oxidative organelles involved in lipid metabolism of long-
chain and branched fatty acids via fatty acid β-oxidation,
lipid synthesis, purine catabolism, and amino acid and glyox-
ylate metabolism. Importantly, most enzymes involved in
these processes produce ROS. For example, acyl-coA oxi-
dase(s), which catalyse the first step in peroxisomal fatty acid
β-oxidation, generates H2O2 [194]. Similarly, xanthine oxi-
dase, cleaved from xanthine dehydrogenase in response to
an increase in calcium extracellular levels (e.g., hypoxia)
and involved in the purine metabolism to uric acid, generates
O2
•- and H2O2 [195, 196]. During peroxisomal amino acid
metabolism, D-amino acid oxidase (catalyses oxidation of
D-amino acids to imino acids) and the L-pipecolic acid oxi-
dase (involved in lysine degradation) generate H2O2. Other
peroxisomal enzymes producing ROS/RNS include L-α-
hydroxyacid oxidase (involved in oxidation of glycolic acid),
polyamine oxidase (involved in polyamine degradation),
sarcosine oxidase (metabolises sarcosine, L-pipecolic acid,
and L-proline), D-aspartate oxidase (catalyses oxidation of
D-aspartate), SOD1, and NOS2 [197, 198].
The ER is involved in diverse functions including protein
folding, processing and vesicular transport, calcium storage,
lipid synthesis, cell signalling, and xenobiotic toxicity. Partic-
ularly, during protein folding, ER oxidoreductin (ERO1)
catalyses oxidation of protein disulfide isomerase, involved
in disulfide bond formation, generating H2O2. Similarly,
quiescin sulfhydryl oxidase, also present in the Golgi, gener-
ates H2O2 for the introduction of disulfide bonds into
unfolded reduced proteins and can compensate for the loss
of ERO1 [199, 200]. The other main source of H2O2 in the
ER is the NADPH oxidase 4 (NOX4). Proteins that belong
to the NOX family are the only cellular enzymes exclusively
involved in the production in ROS by using NAD(P)H for
oxygen reduction to produce a superoxide anion [197].
Finally, the microsomal monooxygenase (MMO) system,
composed of cytochrome P450 (P450), NADPH-P450 reduc-
tase (NPR), and phospholipids, is involved in the oxygena-
tion of several exogenous (xenobiotics) and endogenous
substrates (e.g., heme oxygenase and fatty acid desaturase),
and is one of the major sources of ROS in the ER via electron
leakage from P450 [199].
Other sources of cellular ROS include the plasma mem-
brane and lysosomes, as well as cytosolic reactions [188]. In
addition, ROS production can also be induced in response
to hypoxia (by acting on the mitochondrial ETC and increas-
ing intracellular calcium levels [196, 201, 202]) and starva-
tion, and more generally following environmental stress
(e.g., paraquat), infections, physical exercise, and mental
stress; and increased ROS/RNS levels have been observed
during aging [203–205].
3.2. Dual Roles of ROS and RNS
3.2.1. Beneficial Activities of Free Radicals: Oxidative Eustress.
Crucially, ROS and RNS are not only detrimental to cells, but
they are also important for cellular homeostasis, regulating
numerous important cellular activities, also known as physi-
ological oxidative stress or oxidative eustress. ROS and RNS
act as second messengers in signal transduction pathways
involved in cell survival, cell to cell communication, and cell
growth and proliferation [206–208]. They influence diverse
signalling pathways via oxidation of cysteine sulfhydryl
groups in protein kinases, including protein kinase A
(PKA), PKC, receptor tyrosine kinase (RTK), and Ca2+/-
calmodulin independent protein kinase II (CaMKII). Other
pathways that display crosstalk with ROS/RNS include the
NF-κB pathway, the MAPK pathway, the PI3K/AKT path-
way, ATM signalling, the insulin pathway (e.g., oxidation of
protein tyrosine phosphatase 1B (PTP1B)), iron metabolism
(e.g., Fenton reaction), calcium signalling (e.g., oxidation of
Ca2+ channels, pumps, and exchangers), the ubiquitin system
(the E1, E2, and E3 enzymes have a group of cysteine residues
in their catalytic domains that can be modified by ROS), the
UPS (irreversible oxidation of UPS subunits (e.g., 20S)), and
the autophagy pathway, as will be described later in detail.
In neurons in particular, physiological levels of ROS are
important for (i) axonal growth via cytoskeletal regulation
[209]; (ii) progenitor cell growth via PI3K/AKT signalling
[210]; (iii) neuronal differentiation (a specific redox state is
critical for neuronal development) [211]; (iv) synaptic plas-
ticity, via the control of intracellular calcium release and syn-
aptic vesicle release [212]; and (v) a potential role of NOX
and NOS proteins regulating long-term potentiation (LTP),
pruning, and dendritic growth [213]. In addition, in the
brain, ROS generated by glial cells are also involved in the
modulation of synaptic activity and other metabolic com-
partmentalization/crosstalk with neurons (e.g., astrocytes
supply essential GSH precursors for neurons [214] and, in
hippocampal pyramidal neurons, Atkins et al. described that
ROS are involved in a nonsynaptic glial-neuron crosstalk by
modifying the myelin basic protein in oligodendrocytes
[215]). Most importantly, the presence of these highly reac-
tive species triggers several antioxidant pathways to counter
the accumulation of oxidative stress, and maintain cellular
homeostasis, as will be described later.
3.2.2. Negative Effects of Free Radicals: Oxidative Stress.
ROS/RNS generated inside organelles can be readily
released into the cytoplasm. They diffuse across mem-
branes through aquaporins (e.g., aquaporin 8 for H2O2
release in mitochondria) and other specific unidentified
channels [216]. In the cytosol, these highly reactive mole-
cules modify all classes of macromolecules (i.e., carbohy-
drates, lipids, proteins, and nucleic acids), influence
organellar homeostasis, and ultimately induce cell death
[217–219]. Consistent with this, it has been recently
described that ROS-induced autophagy contributes to fer-
roptosis, a form of programmed cell death based on iron
accumulation [220]. In particular, protein oxidation can
cause loss of activity and/or protein unfolding, with the
tendency to induce intracellular and extracellular protein
oligomers and aggregates that compromise cell viability.
Indeed, this is a primary characteristic of neurodegenera-
tive diseases (e.g., α-syn in Parkinson’s, tau in Alzheimer’s,
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and HTT in Huntington’s) [221]. Lipid peroxidation, trig-
gering degradation of cell membrane components, is also
induced in response to oxidative stress, as lipids are sus-
ceptible to redox modifications; indeed, such changes have
been reported in mDANs in Parkinson’s brains [222].
The nucleus is highly susceptible to oxidative stress. Dif-
fusion of ROS/RNS into the nucleus influences diverse
pathways/components, including chromatin organisation,
DNA methylation, histone function (e.g., nitrated or glu-
tathionylated histones), nucleobases, interactions between
DNA and DNA-binding proteins, mutagenesis, transcription
via targeting of purines and pyrimidines, single- and double-
strand breaks, and abasic site formation [223]. Indeed, oxida-
tive stress can be oncogenic by affecting the expression of
oncogenes [224], and the formation of DNA adducts can
trigger autoimmune disorders [225].
Yoboue et al. proposed a “redox triangle” formed by ER-
mitochondria-peroxisome structures, generating a multior-
ganellar protein complex called the “redoxosome,” where
ROS and RNS accumulate to impact organelle function
(e.g., ER-mitochondria calcium exchange, oxidative
phosphorylation, and protein folding), an idea that awaits
mechanistic validation [197, 226]. Indeed, mitochondria-
associated membranes (MAM) or mitochondria-ER contacts
(MERCs) are modulators of ROS production; calcium cross-
talk and autophagosome formation and aberrant MAM
structure and function are linked to defective autophagy
during neurodegeneration [227–229].
Ultimately, high levels of oxidative stress can induce cell
death via apoptosis, necroptosis, and autophagy-associated
programmed cell death. Indeed, ROS/RNS activate the
extrinsic death receptor pathways (e.g., tumour necrosis fac-
tor receptor family), leading to the activation of caspases, as
well as the internal mitochondrial and ER cell death path-
ways. In mitochondria, ROS can induce apoptosis through
diverse pathways, including activation of p53 and JNK,
which in turn activate proapoptotic Bcl-2 proteins; oxidation
of cardiolipin, leading to cytochrome c release into the cyto-
sol; ATP depletion; and the induction of mitochondrial
membrane depolarization. Low levels of oxidative stress in
the ER activate the unfolded protein response (UPR) to
inhibit protein translation, and to induce chaperone expres-
sion and protein degradation, as will be described later;
whereas high levels of ROS trigger the activation of ER
stress-mediated apoptosis via different pathways (e.g., pro-
longed activation of IRE1α triggers proapoptotic cascades,
upregulation of the proapoptotic transcription factor CHOP,
and activation of proapoptotic Bcl-2 proteins in the ERmem-
brane), some of which are interconnected with mitochon-
drial pathways, leading to caspase activation and apoptosis
[207, 230].
Crucially, the brain is particularly susceptible to oxidative
stress damage. Cobley et al. defined 13 reasons why the brain
is predisposed to oxidative stress and consequent neurodegen-
eration: (i) redox signalling (high levels of ROS/RNS can
induce proapoptotic pathways via redox modifications); (ii)
calcium homeostasis (oxidative stress can lead to calcium
overload and affect mitochondrial function, leading to pro-
grammed cell death); (iii) excessive glutamate uptake (affect-
ing several cellular pathways and producing excitotoxicity);
(iv) glucose metabolism necessary to support neuronal activity
(oxidative stress can affect this pathway via the formation of
advanced end glycation products (AGE)); (v) mitochondria
(there is a high ATP demand in neurons, and elevated
ROS/RNS levels affect mitochondrial function and ATP for-
mation); (vi) neurotransmitter metabolism (e.g., generation
of H2O2 by monoamine oxidase (MOA), whose activity is dis-
rupted in Parkinson’s); (vii) neurotransmitter oxidation (for-
mation of toxic intermediates); (viii) lower antioxidant
response in comparison to other tissues; (ix) microglia activa-
tion and astrogliosis (as a big source for ROS/RNS); (x) pres-
ence of redox active transition metals (e.g., iron and Fenton
reaction); (xi) lipid peroxidation (high levels of fatty acids in
the brain); (xii) NOS and NOX for neuronal signalling; and
(xiii) RNA oxidation [231]. In addition, oxidative stress also
impacts the blood-brain barrier permeability, leading to
increased trafficking of immune cells and neuroinflammation,
another characteristic of neurodegenerative disorders [232].
3.3. Antioxidant Pathways for Controlling Redoxtasis. To
counterbalance oxidative stress, the cell has developed several
antioxidant pathways, including (i) endogenous antioxidant
mechanisms (by the presence of molecules and proteins for
the removal of free radicals), (ii) a metabolic switch to the
pentose phosphate pathway [233], (iii) transcriptional
changes by the activation of specific transcription factors,
(iv) posttranscriptional regulation via redox-sensitive micro-
RNAs, (v) activation of chaperones and specific degradation
systems to avoid protein aggregation, and (vi) the degrada-
tion of damaged organelles [234, 235].
Mitochondria are protected from ROS by the presence of
antioxidant enzymes that contain cysteine catalytic residues
for the reduction of H2O2 into H2O, and by a defence system
for the conversion of O2
•- into the less harmful radical, H2O2,
comprising superoxide dismutase 2 (SOD2) in the mitochon-
drial matrix, and SOD1 in the intermembrane space. Gluta-
thione peroxidases (GPX1 and GPX4) in the outer
mitochondrial membrane, reduce H2O2 into H2O, using
reduced glutathione (GSH) as cofactor. Other mitochondrial
antioxidant enzymes include the peroxiredoxins (PRX3 and
PRX5), which also catalyse the reduction of H2O2 into H2O
[197, 236]. Peroxisomes are the other major centre for anti-
oxidant enzyme function. The main ROS defence system
here is catalase, which catalyses the reduction of H2O2 into
H2O, and indeed deficiencies in this system are linked to can-
cer and diabetes. In addition, in this organelle, SOD1 and
PRX5 are also involved in the formation and reduction of
H2O2, respectively [197, 237]. The ER also houses antioxi-
dant mechanisms, by the presence of GPX7, GPX8, and
PRX4 [197]. Other antioxidant molecules in the cell include
ascorbic acid, uric acid, melatonin, ubiquinol, and some vita-
mins, which neutralize free radicals by donating electrons
and other regulators of redox signalling, including the elec-
tron donor groups thioredoxins (TXN) and glutaredoxins
(GRX) [238]. An additional layer of regulated antioxidant
response is via cellular metabolic reconfiguration. Here, cel-
lular metabolism is redirected towards the pentose phospha-
tase pathway, leading to the formation of NADPH which is
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used by glutathione reductase for GSH reduction, a crucial
step in responsive redoxtasis [233, 239].
Transcriptionally, NRF2 is considered to be a master reg-
ulator of redoxtasis, controlling around 1% of human genes
that share in common the Antioxidant Response Element
(ARE) in their promoters [240–243]. Crucially, redox regula-
tion by NRF2 via increasing reduced TXN is also crucial for
the modulation of apoptosis signal-regulating kinase 1
(ASK1) activity, involved in ER-stress neuronal cell death
[244, 245]. One of the main mechanisms of regulation that
cooperate to maintain NRF2 levels within physiological values
is KEAP1 (Kelch-like ECH-associated protein 1), a redox-
regulated E3 ubiquitin ligase substrate adaptor that promotes
NRF2 degradation under basal conditions. High levels of oxi-
dative stress modify KEAP1 to impair its function, leading to
increased NRF2 that translocates to the nucleus [246]. This
factor regulates the expression of genes involved in redox
homeostasis (like Heme Oxigenase-1 (HO-1)) as well as in
metabolic detoxification (like NAD(P)H quinone oxidoreduc-
tase (NQO1)), inflammation, and proteostasis [247]. In
addition, posttranscriptional antioxidant regulation via micro-
RNAs also target this pathway [234].
Finally, the two major quality control mechanisms in the
cell have antioxidant roles in preventing the aggregation of
oxidized proteins and/or the persistence of damaged organ-
elles (namely, the ubiquitin-proteasome system (UPS) and
autophagy [1, 2, 5–7]). Here, we focus on the interplay
between autophagy, redox homeostasis, and transcriptional
control.
4. Autophagy and Redoxtasis Crosstalk
Under stress conditions (e.g., starvation, hypoxia, and
uncouplers), ROS/RNS are induced, and have the potential
to influence autophagy via core autophagy protein oxidation,
or by altering the activities of transcription factors [248–250].
In addition, several lines of evidence suggest that indirect
activation of autophagy in response to ROS damage, includ-
ing DNA oxidation and lipid peroxidation, is crucial for cell
survival [251–253]. As ROS damages organelles and biomol-
ecules, their repair and/or removal by fusion/fission or
autophagic degradation (e.g., mitophagy; pexophagy; ER-
phagy; aggrephagy) is a crucial facet of any ROS response.
Thus, a delicate balance is needed between elevated oxidative
stress promoting organelle quality control, and its negative
effects on components of the autophagy machinery [254,
255] (Figure 1).
4.1. Redox Modifications of Autophagy Proteins: Upstream
Pathways/Autophagy Induction. The activity of several pro-
teins upstream of the autophagy pathway is affected by
ROS/RNS. These proteins are typically also involved in the
regulation of several pathways; thus, their redox modifica-
tions influence diverse cellular activities.
4.1.1. Receptor Tyrosine Kinases (RTK) for the Activation of
PI3K/AKT via Growth Factors (e.g., EGF). Reversible oxida-
tive and nitrosative modifications include sulfenylation, glu-
tathionylation, disulfide bonds, acylation, and nitrosylation.
These affect RTK receptors (including EGFR, FGF, RET,
and VEGFR), affecting their activation, localisation, or traf-
ficking, depending on the modification and residues involved
(a recent review collecting all known modifications and
effects can be found in [256]). In addition, PTP1B activity,
involved in the inhibition of RTK signalling, is also affected
by oxidation reactions, including sulfenylation, nitrosylation,
and glutathionylation [256].
4.1.2. Phosphatase and Tensin Homolog (PTEN). PTEN
opposes PI3K activity by dephosphorylating PIP3 and inhi-
biting AKT signalling. Redox modifications affect PTEN
activity; for example, (i) H2O2 oxidation inactivates PTEN
catalytic activity by the formation of disulfide bonds (C124-
C71), leading to autophagy activation in a noncanonical
pathway induced my mTOR activation; and (ii) peroxynitrite
inhibits PTEN activity and induces neuronal survival and can
be oxidized by a lipid peroxide which is prevented by PRX3
[257–259].
4.1.3. Phosphoinositide-Dependent Kinase 1 (PDK1). PDK1 is
a Ser/Thr kinase that activates AKT. Redox modifications of
this protein include nitrosylation in different residues leading
to inhibition of its kinase activity [260].
4.1.4. AKT. Several cysteines within the pleckstrin homology
domain of AKT have been identified as being reversibly oxi-
dised, forming new disulfide bonds. These modifications
affect protein function, including the stabilisation of the
PI3P pocket, or its inhibition, depending on the modifica-
tion. In addition, AKT can be inactivated via glutathionyla-
tion, which is reversed by glutaredoxin 1 [261, 262].
4.1.5. TSC2. Nitrosylation of TSC2 impairs its dimerization
with TSC1, leading to mTOR activation [263].
4.1.6. mTORC1. Generation of disulfide bonds affects mTOR
stability and activity depending on the residues involved.
Oxidised mTOR can be rescued by Thioredoxin 1 [264].
Related to this, lysosomes can also sense redox signalling
specifically via redox-sensing lysosomal ion channels [265].
4.1.7. AMPK. Disulfide bonds, sulfenylation, and glutathio-
nylations have been described to be present in both α and β
AMPK subunits, affecting AMPK activity depending on the
modified residues (e.g., disulfide bonds result in AMPK inhi-
bition, and this is reversed by Thioredoxin 1 but other redox
modifications result in AMPK activation). In addition, free
radicals induce calcium release (e.g., in hypoxia) leading indi-
rectly to the activation of the AMPK via CaMKII activation.
Similarly, it has been reported that the induction of autoph-
agy, as a consequence of ROS production in starvation
conditions and ATP depletion, is via activation of the AMPK
pathway [266–270].
4.1.8. Ataxia Telangiectasia Mutated Protein Kinase (ATM).
ATM is a threonine/serine kinase involved in the DNA
damage/repair response. Crucially, ATM is also involved in
the induction of pexophagy to maintain redox balance. In
response to ROS, ATM activates MAPK, and ATM is trans-
ported into peroxisomes via the PEX5 import receptor. Here,
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it phosphorylates PEX5 triggering ubiquitylation via the E3-
like ubiquitin ligase complex, PEX2-PEX10-PEX12, and later
recognition by cargo receptors [271, 272]. H2O2 treatment
induces nuclear ATM redox disulfide bond formation, indi-
rectly promoting the downstream expression of proteins
involved in the pentose phosphate pathway, and an activator
effect via nytrosilation has also been suggested [273–275].
4.1.9. Sirtuin 1 (SIRT1). A class III histone deacetylase regu-
lating numerous cell activities (e.g., glucose metabolism,
chromatin silencing, inflammation, and lipid metabolism)
[276], SIRT1 is involved in autophagy via the release of
nuclear LC3 during starvation and the deacetylation of
ATG5 and ATG7 [277, 278]. In addition, in response to
ROS, it is involved in the activation via deacetylation of sev-
eral autophagy transcription factors, including FOXOs, p53,
NRF2, HIF-1α, NF-κB, PPARs, and FXR [276, 279]. Con-
versely, SIRT1 translocation to the nucleus is induced indi-
rectly by the presence of ROS, but SIRT1 can also be
modified via oxidation, inhibiting its activity [280–282].
4.1.10. UPR. Numerous redox modifications have been
described for the ER stress-sensing proteins, IRE1α, PERK,
and ATF6 (for a recent review, see [283]). For example, cys-
teine sulfenylation of cytosolic IRE1α blocks UPR activation,
but it induces the antioxidant NRF2 pathway [284]. Other
modifications include activation of PERK kinase activity via
nitrosylation [285], and disulfide bridge formation in ATF6
in unstressed ER [286].
4.1.11. The Cytoskeleton. It is also important to mention that
redox modifications can also affect cytoskeletal dynamics
[287], and thus, indirectly, autophagy efficiency.
4.2. Redox Modifications of Autophagy Proteins: Autophagy
Proteins Involved in the Assembly Pathway and Selective
Autophagy. Proteins involved in the autophagosome assem-
bly pathway can also be targeted by ROS/RNS. These redox
modifications affect the efficiency and productivity of autop-
hagosome biogenesis (Figure 1).
4.2.1. ATG4. ATG8 processing mediated by ATG4 proteins
needs to be spatiotemporally regulated to support both
autophagy initiation and the availability of a pool of primed
ATG8 [288]. Scherz-Shouval et al. found that ROS, produced
during starvation, are essential for autophagy via regulation
of ATG4. They described a cysteine residue near the catalytic
site that is a target for oxidation, thus increasing autophagy
initiation by blocking ATG4-mediated delipidation in the
vicinity of the expanding autophagosome (exemplified by
ATG4A) [289]. Later, Qiao et al. described that ROS induces
the formation of a prooxidant complex called REDD1-
TXNIP, which inhibits ATG4B function leading to autoph-
agy activation [290]. In addition, Perez-Perez et al. described
an inhibitory redox modification in ATG4 in yeast, via the
formation of disulfide bonds outside the catalytic site, which
can be reversed by Thioredoxin 1 [291]. Finally, nitrosylated
ATG4 has been observed in the hippocampal neurons of dia-
betic rats, and in vitro, in neuronal cells in hyperglycemia
conditions leading to neurotoxicity [292].
4.2.2. ATG3 and ATG7. Frudd et al. described that these pro-
teins can be modified by oxidation, including glutathionyla-
tion and disulfide bond formation, affecting their function,
and leading to autophagy inhibition. Conversely, while inac-
tive, ATG3 and ATG7 form covalent thioester complexes
with LC3, preventing their oxidation. However, after autoph-
agy induction, their interactions become more transient, thus
increasing susceptibility to redox modifications [293].
4.2.3. BECLIN1. Redox modifications affect BECLIN1 func-
tion indirectly: under normal conditions, BECLIN1 forms a
complex with proapoptotic BCL-2, which inhibits BECLIN1
activity; however, under autophagy-inducing conditions,
BECLIN1 dissociates to establish the PI3KC3 complex. Kitada
et al. described that BCL-2 is a target of redox modification,
particularly nitrosylation, stabilising the interaction with
BECLIN1, and thus preventing autophagy induction [276].
4.2.4. p62/SQSTM1. Carroll et al. identified two cysteine res-
idues in p62/SQSTM1 that can be redox modified, forming
disulfide bonds that promote its oligomerisation to enable
autophagy induction [294]. They further highlighted the
potential effect of p62/SQSTM1 oxidation in aging [294].
4.2.5. Parkin/PKRN. Numerous redox modifications have
been described for Parkin, including nitrosylation, sulfona-
tion, and methionine oxidation. Particularly, Chung et al.
described that S-nitrosylation reduces Parkin E3 ligase activ-
ity, thus affecting its protective function [295], although
some discrepancies were reported by a different group
[296]. Similarly, Ozawa et al. reported a new site of nitrosyla-
tion in Parkin that leads to mitophagy induction via activa-
tion of its ligase activity [297]. In addition, Meng et al.
described that Parkin can be sulfonated in an in vitro Parkin-
son’s model, leading to protein aggregation, and possibly
contributing to the formation of Lewy’s bodies in Parkinson’s
[298]. However, in a recent article (at preprint stage at the
point of writing this review), Tokarew et al. highlighted the
importance of Parkin’s own oxidation in neuroprotection
[299]. Previously, Vandiver et al. showed that Parkin can also
undergo sulfhydration, enhancing its catalytic activity and its
protective function [300]. In addition, they described that in
Parkinson’s brains, Parkin is highly nitrosylated, but that
sulfhydration is reduced [300]. Lee et al. recently reported
that Parkin can also undergo methionine oxidation at
M192, a residue mutated in early onset Parkinson’s [301],
and that this is reversed by methionine sulfoxide reductase
B2 (MSRB2) released in response to damaged mitochondria,
thereby promoting mitophagy [302]. Finally, El Kodsi et al.
have reported that Parkin can be glutathionylated in an anti-
oxidant reaction (at preprint stage at the point of writing this
review) [303].
4.2.6. PINK1. Oh et al. described that PINK1 can be nitrosy-
lated, inhibiting its kinase activity, and this posttranslational
modification is present in Parkinson’s mice models where
Parkin recruitment is reduced, restricting mitophagy [304].
4.2.7. Protein Deglycase (DJ-1). DJ-1 overexpression induces
mitophagy via the activation of ERK in mDANs, and this
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protects against rotenone-induced cell death [305]. Indeed,
mutations in DJ-1 are linked to familial Parkinson’s and
some studies suggest that oxidised DJ-1 could potentially be
used as a biomarker for Parkinson’s [306]. Canet-Aviles
et al. observed that cysteine-sulfinic acid formation in DJ-1
is necessary for mitochondrial targeting and neuroprotection
[307], and consistent with this, Zhou et al. demonstrated that
the sulfinic DJ-1 isoform prevents α-synuclein fibrillation
[308]. Conversely, in the presence of high levels of oxidative
stress, DJ-1 is oxidised to the sulfonic form; this isoform is
inactive and predisposed to aggregate formation, and indeed,
this overoxidised isoform has been detected in brains from
Parkinson’s patients [309, 310]. In addition, Ozawa et al.
highlighted the crucial role of DJ-1 in the nitrosylation of
Parkin, and suggested that DJ-1 inactivation reduces mito-
phagy, leading to mitochondrial dysfunction and Parkinson’s
pathogenesis [311].
4.3. Redox Modifications of Autophagy Proteins: Autophagy
Transcriptional Control. Autophagy gene expression is influ-
enced in different tissues by diverse transcription factors,
microRNAs (miRNAs), and by epigenetic modifications
[312]. In the last decade, several studies have pointed out that
“nuclear” control of autophagy is key for the regulation of the
autophagy process, including short-term and long-term out-
comes [312]. Currently, numerous transcription factors
involved in the regulation of this process have been
described. Notable amongst these is transcription factor EB
(TFEB), a member of the basic helix-loop-helix leucine-
zipper family of transcription factors. TFEB is considered to
be a master regulator of autophagy that, under starvation
conditions, translocates to the nucleus, where it regulates
more than 200 lysosomal-related genes and autophagy genes
(including ATG4, ATG9B, BECLIN1, LC3B, GABARAPL1,
ATG16, WIPI, UVRAG, and p62/SQSTM1) by binding to
CLEAR (coordinated lysosomal expression and regulation
network) sequences in their promoters. These genes are
involved in autophagosome biogenesis, autophagosome-
lysosome fusion, and lysosomal biogenesis [313, 314]. TFEB
translocation is regulated primarily by phosphorylation
[313, 315], via ERK2 (at S142), and via the autophagy inhib-
itor mTORC1 (at S211 and S142), to retain TFEB in the cyto-
plasm by binding to 14-3-3 proteins [314, 316, 317].
Phosphorylated TFEB is also targeted to the proteasome via
the E3-like enzyme, STIP1 homology and U-Box-
containing protein 1 (STUB1), thereby controlling its stabil-
ity [318]. Calcineurin, activated by lysosomal calcium release
via mucolipin 1 (MCOLN1), binds and dephosphorylates
TFEB, causing dissociation from 14-3-3 proteins and translo-
cation to the nucleus [319–321]. Cytoplasmic-nuclear shut-
tling of TFEB is also observed after refeeding, here
modulated via mTORC1 phosphorylation at residues close
to the nuclear exported signal (NES) (S142 and S138), with
translocation mediated by exportin 1 [322]. An increase in
the phosphorylated form of TFEB and dysregulation of
autophagy has been correlated with the progression of neuro-
degenerative diseases, including Parkinson’s [323, 324]. In
addition, overexpression of TFEB has been reported to be
beneficial in numerous disease models via clearance of aggre-
gated protein (e.g., tau in Alzheimer’s, α-syn in Parkinson’s,
and HTT in Huntington’s [325–327]).
In this review, we focus on transcription factors whose
activity is regulated by redox modifications, thus affecting
autophagy transcriptional control.
4.3.1. TFEB. In addition to the well-characterised control of
TFEB activities via phosphorylation (above), Wang et al.
described the regulation of TFEB (and other members of
the MiT family) via ROS-mediated cysteine oxidation
(C212). This inhibits the interaction of TFEB with Rag
GTPases, and induces its nuclear translocation, thus induc-
ing the expression of autophagy/lysosomal genes indepen-
dently of mTORC1 (although its role in neurodegenerative
diseases remains elusive) [328].
4.3.2. The FOXO Family. In particular, FOXO1 and FOXO3
have been identified as autophagy transcription factors, regu-
lating the expression of numerous autophagy-related genes
[329–331]. In addition, FOXOs also regulate the expression
of antioxidant genes, including SOD1, SOD2, and GPX1
[332]. Under basal conditions, FOXOs are phosphorylated
by AKT and retained in the cytosol through binding to 14-
3-3 [333]. Under stress conditions, they become activated
and can either translocate to the nucleus or regulate autoph-
agy in the cytosol—acetylated FOXO1 (under oxidative stress
conditions) can bind to ATG7 and activate it [329, 334, 335].
Crucially, it was shown recently that FOXO3a can be
degraded by the autophagy pathway, suggesting a negative
feedback mechanism for this transcription factor [336].
Mainly, examples of indirect redox regulation of the FOXO
family have been described, although direct modifications
via formation of disulfide bonds between FOXOs and other
proteins have also been reported (e.g., disulfide bridges
between FOXO4 and transportin-1 to induce nuclear trans-
location in response to ROS [337] and disulfide bond hetero-
trimers between FOXO3, PRX1, and Importin-7/Importin-8,
inducing an antioxidant response [338, 339]). Gomez-Puerto
et al. reported that FOXO3 is phosphorylated by MAPK and
nuclear translocated in response to H2O2 treatment in
human mesenchymal stem cells, thus leading to autophagy
induction that is crucial for osteogenic differentiation; how-
ever, a direct redox modification has not yet been described
[340]. Other examples of indirect redox regulation of the
FOXO family include redox modifications of signalling
proteins upstream of FOXO, including SIRT1 and AKT, as
previously described [332].
4.3.3. NRF2. The master regulator of oxidative stress, NRF2
contributes to the regulation of autophagy-gene expression
under these conditions (e.g., p62/SQSTM1, NDP52, ULK1,
ATG2B, ATG4, ATG5, and GABARAPL1) [341]. Crucially,
as mentioned before, the main canonical redox regulator of
NRF2 is the NRF2-inhibitor protein KEAP1. Several cysteine
residues in KEAP1 can be oxidised leading to conformational
changes and thereby preventing NRF2 degradation [342]. In
addition, p62/SQSTM1 also binds to KEAP1, marking it for
degradation; meanwhile, TFEB represses the NRF2-
ubiquitin ligase, DCAF11 (DDB1- and CUL4-associated
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factor 11)), ultimately promoting NRF2 translocation to the
nucleus [343, 344] to establish a feed-forward loop. Finally,
there is some evidence indicating that NRF2 is also subject
to redox cysteine modifications, promoting NRF2 nuclear
translocation; consistent with this, mutations in these cyste-
ines enhance interactions with KEAP1, thus increasing
NRF2 degradation [345]. Conversely, recent evidence sug-
gests that NRF2 also regulates CMA via LAMP2A expression
[346]. In addition, NRF2 directly regulates HIF-1α expres-
sion, and interacts with ATF4 [347, 348], master regulators
of O2 homeostasis and contributors to autophagy-gene
expression (in mild hypoxia, HIF-1α activates the transcrip-
tion of mitophagy genes (e.g., NIX); whereas in severe
hypoxia, ATF4 regulates the expression of autophagy genes
(e.g., ULK1 and LC3B) [349, 350]). Both, in turn, are
regulated by ROS, and act as antioxidant and antiapoptotic
proteins [351–354].
4.3.4. P53. As one of the best characterised transcription fac-
tors, p53 has been reported to regulate antioxidant genes
(e.g., GPX1) [355], autophagy genes after DNA damage
(e.g., ULK1, ATG4, ATG7, and ATG10), and to induce TFEB
nuclear translocation [356]. It also stabilises NRF2 indirectly
by regulating the expression of p21 and SESN2, prominent
KEAP1 interactors [357]. However, cytoplasmic p53 inhibits
autophagy via posttranscriptional downregulation of LC3A
[358]. Several redox modifications have been reported in
p53, including glutathionylation and nitrosylation at residues
near the DNA-binding domain, with the former causing
inhibition of p53 DNA binding [359]. Indeed, previous data
suggest that glutathionylated p53 may be involved in Alzhei-
mer’s neurodegeneration [360]; however, nitrosylation seems
to be essential for DNA binding and antioxidant gene expres-
sion [361].
4.3.5. NF-κB. Under basal conditions, the proinflammatory
transcription factor, NF-κB, is inactivated in the cytosol
where it interacts with IκB (inhibitor of κB) preventing its
nuclear translocation. Previous data suggest that oxidative
stress can induce or inhibit the NF-κB pathway, depending
on conditions [362]. As one example of indirect regulation,
IκB is phosphorylated under oxidative stress, leading to its
polyubiquitination and consequent degradation [363]. The
consequent elevation of nuclear NF-κB upregulates the
expression of several anti-inflammatory and antioxidant
genes (e.g., HO-1, Thioredoxin 1, GPX1, NOS2, and SOD2)
[364], and can induce or inhibit autophagy depending on
the context (i.e., NF-κB mainly inhibits autophagy, but it
can also activate the expression of the autophagy genes
including BECN1 and p62/SQSTM1 [365–367]). ROS can
also directly regulate NF-κB activity. Disulfide bonds in cys-
teine in the DNA-binding domain inhibits DNA binding,
and this can be rescued by Thioredoxin 1 [368]. Similarly,
other redox modifications in NF-κB including glutathionyla-
tion and nitrosylation also inhibit DNA binding [369, 370].
4.3.6. Other Transcription Factors. Examples of other tran-
scription factors involved in both the regulation of
autophagy-related and antioxidant genes include (i) the
peroxisome proliferator-activated receptors (PPARs) that
upregulate autophagy and can be directly regulated by redox
modifications (e.g., nitrosylation) [365, 371, 372] and (ii) the
transcription factor, farnesoid X receptor (FXR), mainly
expressed in liver and intestine, a nuclear receptor involved
in metabolism [373–375]. Under fed conditions in liver, FXR
inhibits autophagy-gene regulation directly (e.g., ULK1,
ATG2, ATG5, ATG7, WIPI, GABARAP, and TFEB) [376].
5. Autophagy and Oxidative
Stress in Parkinson’s
Parkinson’s is one of the most common neurodegenerative
disorders, second only in prominence to Alzheimer’s, and it
affects 1-3% of the population aged over 60 [377, 378]. Life
expectancy can be lower in many Parkinson’s patients
[379], due to an increased risk of developing other diseases
including infections (pneumonia being the most common
cause of death in Parkinson’s) [380, 381], certain types of
cancers (e.g., brain and breast cancer; although, generally,
there is an inverse association between cancer and Parkin-
son’s [382]), and cardiovascular disease [383]. In the UK,
the number of Parkinson’s patients in 2018 according to
the Parkinson’s UK website [384] was estimated to be
145,500, and this is predicted to reach 250,000 by 2065. This
incidence is affected by age, gender, environmental factors
[385], and genetics (10-15% of Parkinson’s cases are familial
[386], with several recognised Parkinson’s-associated genes
[387]). In patients, the main symptoms are motor problems
including bradykinesia (slowness of movement), hypokinesia
(paucity of movements), postural instability (balance impair-
ment), tremor at rest, muscle rigidity, and gait problems
(walking abnormalities), with mild cognitive impairments,
sleep disorders, and impulsive behaviours also common
[388–390].
At the cellular level, Parkinson’s is characterised by the
loss of mDANs, initially in the substantia nigra pars com-
pacta (SNc). As the condition progresses, defects in seroto-
nergic, noradrenergic, cholinergic, GABAergic, and
glutamatergic neuronal pathways can also be observed
[391]. Although the exact causes of neuronal loss in Parkin-
son’s are not known, the hallmarks that characterise this dis-
ease include (i) the accumulation of α-syn-rich Lewy’s
bodies; (ii) increased oxidative stress accompanied by a
reduction in antioxidants; (iii) neuroinflammation; (iv) mito-
chondrial dysfunction; (v) ER stress; (vi) and disruption in
protein quality control, including autophagy dysregulation
[392]. Crucially, mDANs appear to be particularly sensitive
to autophagy deficits, and are frequently exposed to high
levels of oxidative stress [96, 231, 325, 393–396]. In the fol-
lowing sections, we will summarise how these two processes
are interconnected, and the links with other Parkinson’s
hallmarks (Figure 2).
5.1. Midbrain Dopaminergic Neurons and Degeneration of
the Nigrostriatal Pathway. mDANs are localized in the mes-
encephalon, and are characterised by the production of the
catecholaminergic neurotransmitter, dopamine [397]. Dopa-
mine belongs to the monoamine neurotransmitter group that
14 Oxidative Medicine and Cellular Longevity
also contains serotonergic or 5-hydroxytryptamine (5-HT)
and noradrenergic neurotransmitters [398]. Dopamine bio-
synthesis occurs by a two-step process in the mDAN cytosol,
and is considered the key element of the oxidative stress the-
ory in Parkinson’s: (i) tyrosine is hydroxylated to L-DOPA by
tyrosine hydroxylase (TH), an enzyme that can also oxidise
L-DOPA leading to ROS production [399]; and (ii) L-
DOPA is then decarboxylated to dopamine by the aromatic
amino acid decarboxylase (AADC), which can be further oxi-
dised as will be described later. Subsequently, dopamine is
incorporated into synaptic vesicles via the vesicular mono-
amine transporter 2 (VMAT2). Inside these vesicles, dopa-
mine is stabilised by the acidic pH. Ultimately, the
neurotransmitter is released into the synapse for signal trans-
duction [400]. Dopamine receptors include D1-like receptors
(D1 and D5) and D2-like receptors (D2, D3, and D4). [401],
and these differ in their localisations within the brain, their
modes of action (D1-like receptors activate adenylate cyclase
(AC) whereas D2-like receptors inhibit its activation), and
their functional influences (e.g., locomotion, emotion,
appetite, learning, attention, reward, and memory) [401].
Dopamine reuptake from the extracellular space into presyn-
aptic neurons is regulated by the dopamine transporter
(DAT) [402].
There are three different clusters of mDANs, designated
as follows: (i) A8, those originating from the retrorubral field
(RRF); (ii) A10, those found in the ventral tegmental area
(VTA) forming the mesolimbic (to the nucleus accumbens)
and mesocortic (to the frontal cortex) dopaminergic path-
ways; and (iii) A9, the cells located in the SNc that project
to the striatum. Functionally, mDANs involved in emotion-
based behavior are found in the A8 and A10 groups, whereas
those responsible for voluntary movement control are speci-
fied as A9 [403]. As A9 SNc mDANs are the first to be lost in
Parkinson’s, it is worth focusing on the enhanced vulnerabil-
ity of these cells. In healthy individuals, voluntary movement
is controlled in the basal ganglia via a direct (to increase
motor activity) and an indirect (to decrease motor activity)
pathway that conveys signals to the motor cortex via the thal-
amus, and from there, on to the spinal cord [404]. In Parkin-
son’s, loss of mDANs correlates with a reduction in
























































Figure 2: Oxidative stress and autophagy dysregulation in Parkinson’s. Oxidative stress and autophagy dysregulation are interconnected in
the dopaminergic neurons affected in Parkinson’s. In addition, several conditions contribute to this destructive imbalance leading to neuronal
death and progressive neurodegeneration, including a reduction in antioxidant pathways (e.g., a reduction in endogenous antioxidant
mechanisms and antioxidant transcription factors); ER stress; mitochondrial dysfunction; mutations in key proteins modulating these
processes (familial Parkinson’s); disruption of the cytoskeleton; UPS dysfunction; neuroinflammation; high levels of calcium and iron,
leading to neurotoxicity; neurotoxins (e.g., MPTP and rotenone); and α-syn aggregation in Lewy’s bodies.
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pathway and hyperactivation of the indirect pathway, with an
overall increase in thalamus inhibition and reduced
voluntary movement being the net effect [405, 406].
Perhaps the most compelling explanation for the vulner-
ability of mDANs is that their atypical morphology and
physiology require that these cells operate close to their
energy demand/supply threshold [407]. A9 mDANs have
very long, unmyelinated axons, with extensive arborisation,
and abundant synapses with unique electrophysiological
properties [408–411]. They display autonomous low-
frequency pace-making activity, controlled by L-type
(Cav1) Ca2+ channels, to provide tonic dopamine release to
the striatum [407]. This burdens them with the additional
challenge of coping with excess cytosolic Ca2+. Unfortu-
nately, SNc mDANs have intrinsically low Ca2+-buffering
capacity, unlike their counterparts in the neighbouring
VTA, thus placing an extra reliance on energy-dependent
Ca2+ efflux and Ca2+ sequestration in mitochondria [412–
415]. Although high mitochondrial Ca2+ supports enhanced
oxidative phosphorylation (OXPHOS) rates [416], this
comes at the expense of increased mitochondrial oxidative
stress [417]. In addition, increased mitochondrial activity
results in high levels of cellular iron content due to the
numerous mitochondrial enzymes using it as a cofactor.
Numerous publications have reported an increased vulnera-
bility of mDANs to iron-induced oxidative stress (e.g., dopa-
mine oxidation), and iron chelators have a neuroprotective
effect [418–421]. Indeed, the generation of ROS may result
from a disruption of aerobic metabolism. The resulting
steady decline in mitochondrial fitness ultimately leads to
apoptosis [412, 414], and for this reason, efficient mitochon-
drial quality control mechanisms are needed to maintain a
healthy mitochondrial population in these cells. In addition,
their characteristic neuronal morphology, with extensive
arborisation and numerous axonal terminals, creates a high
energetic demand to sustain their abundant synapses, indi-
cated by the higher density of axonal mitochondria and high
dependency on the cellular trafficking machinery [417, 422].
Perhaps most tellingly, neurotoxins that target mitochon-
dria can induce selective mDAN cell death. A neurotoxin
used to generate Parkinson’s mouse models, 1-methyl 4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP), inhibits mitochon-
drial Complex I in the ETC, causing ROS damage and
mitochondrial dysfunction [423]. MPTP can cross the
blood-brain barrier, it is metabolised to MPP+ and trans-
ported by DAT into mDANs [424]. Another Complex I
inhibitor is the hydrophobic toxin rotenone, and this can also
cross the blood-brain barrier to freely diffuse into cells. Sev-
eral studies suggest a selective vulnerability of dopaminergic
neurons to this compound, and it has been widely used as a
Parkinson’s-inducing model [425–429]. Rotenone acts by
inducing an increase in ROS production, elevating mito-
chondria bioenergetics, dysregulating intracellular calcium
homeostasis, dysregulating autophagy, and altering lipid
and glutamine metabolism [417, 430–433]. Other examples
of neurotoxins affecting mitochondrial function that are
commonly used as Parkinson’s models include 6-
hydroxydopamine (6-OHDA) and paraquat, causing neuro-
degeneration via mitochondrial dysfunction and increase in
free radicals [424, 434]. In the following sections, we discuss
how redox imbalance in the Parkinson’s brain affects
autophagy pathways to exacerbate the disease.
5.2. Autophagy Dysregulation in Parkinson’s and Its Interplay
with Oxidative Stress. Elevated levels of oxidative stress in
Parkinson’s correlate with lipid peroxidation, nucleic acid
oxidation, elevation of intracellular calcium and increased
iron content, and protein oxidation and nitration [395,
435]. In addition, antioxidant deficiencies have been
observed in Parkinson’s (e.g., low levels of thioredoxin reduc-
tase 1 and glutathione peroxidase) [436–438], and might be
involved in the aggravation of the disease at early stages
(e.g., in early stages of an α-syn Parkinson’s model, Nrf2 defi-
ciency increased dopaminergic cell death, neuroinflamma-
tion, and protein aggregation [439]),while upregulation of
antioxidant pathways appear to be beneficial as a potential
therapeutic target (e.g., upregulation of the NRF2 pathway
prevents neuronal death in MPTP and α-syn Parkinson’s
mice models [440, 441] and restores defective locomotor
activity in a Drosophila Parkinson’s model [442]). On the
other hand, increased immunoreactivity of ROS-producing
enzymes, particularly NOX complexes, has also been
observed in Parkinson’s [443], and indeed, NOX2 activation
in a rotenone-induced Parkinson’s model impairs autophagy
and induces cell death [444], while inactivation of NOX
complexes has a neuroprotective effect [445].
One of the main features of oxidative stress in mDANs is
the oxidation of dopamine. In dopaminergic neurons, cyto-
solic excess dopamine is oxidised to the metabolite amino-
chrome or other toxic dopamine quinones. These are
intermediates in the normal process of dopamine oxidation
to neuromelanin, a dark polymer pigment that accumulates
with age in the SNc and has neuroprotective roles as a metal
chelator (e.g., preventing iron-mediated oxidative damage)
[446, 447]. Aminochrome is toxic, and has been proposed
to play an important role in the neurodegenerative process
through different mechanisms: (i) the formation and stabili-
sation of neurotoxic protofibrils of α-syn aggregates [448];
(ii) mitochondrial dysfunction by inhibiting Complex I
[449]; (iii) cytoskeletal disruption and impairment of axonal
transport, with restricted autophagosome-lysosome fusion
and lysosomal dysfunction [450, 451]; and (iv) neuroinflam-
mation via the activation of microglia and astrocytes [452].
Consequently, aminochrome contributes to autophagy
impairment both cell autonomously [453], and noncell
autonomously via neuroinflammation, which itself is linked
to glial autophagy dysfunction (e.g., the inflammatory
cytokine, TNFα, impairs autophagy flux in microglia via
mTORC1 [454]).
Over the previous decade, numerous lines of evidence
have highlighted the importance of autophagy in neuronal
homeostasis. In the absence of autophagy in dopaminergic
neurons (in Atg7 knockout mice), inclusions containing α-
syn and p62/SQSTM1 are observed predominantly in neur-
ites, and these increase with age, preempting neurodegenera-
tion and motor dysfunction [96]. Particularly, the location of
autophagic structures and cargo needs to be considered due
to the unique characteristics of autophagosome assembly,
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maturation, and trafficking in neurons (e.g., fewer autopha-
gosomes in the soma might be an indication of disrupted ret-
rograde transport from the distal axon, including oxidative
modifications that can affect the cytoskeleton) [287, 455–
457]. This implicates autophagy in mDAN protection, and
indeed, genetic autophagy induction (BECN1, TFEB, and
LAMP2A overexpression) in α-syn (SNCA) overexpression
mouse models ameliorates synaptic and dendritic pathology
[325, 458, 459], while induction via rapamycin (mTORC1
inhibitor) treatment in induced pluripotent stem cell-
(iPSC-) derived neurons promotes clearance of α-syn aggre-
gates and reduces oxidative stress levels in a paraquat-
induced Parkinson’s mice model [105, 460]. Conversely,
Hunn et al. in 2019 showed that impaired macroautophagy
(Atg7 conditional knockout) in a SNCA mouse model led to
dopamine release and improved motor movement, while
aggravating pathology as reported by increased p62/SQSTM1
inclusions and neuronal death [461]. In addition, it is known
that inefficient mitophagy plays an important role in the
pathogenesis of Parkinson’s, including an accumulation of
mitochondrial ROS [462], an observation that correlates with
the high vulnerability of SNc mDANs with high energetic
demands. Mutations in PINK1, PRKN/Parkin, and
FBXO7—three proteins involved in the recognition of dam-
aged mitochondria—are linked to familial Parkinson’s (iden-
tified as PARK2, PARK6, and PARK15, respectively) [463]. In
addition, as previously described, redox modifications have
been described for PINK1 and Parkin, highlighting the inter-
play between these two pathways. Indeed, in hiPSC-based
Parkinson’s disease models, PINK1 nitrosylation—also
observed in transgenic Parkinson’s mice models—correlates
with reduced Parkin recruitment efficiency and mitophagy
disruption [304]. Similarly, oxidised forms of Parkin have
been described in Parkinson’s, including Parkin sulfonation
linked to protein aggregation (including Lewy’s body forma-
tion and associated redox changes) in an in vitro MPTP-
induced Parkinson’s model (for a description of all oxidised
Parkin forms, see Section 4.2) [295, 298, 300]. In addition,
in zebrafish, loss of Nipsnap1—a mitochondrial matrix
protein involved in PINK1/Parkin-independent mitophagy
and highly expressed in mDANs—caused Parkinson’s hall-
marks [9, 135]. In the light of these findings, an autophagy
inducer, Nilotinib, is currently in clinical trial for Parkinson’s
[464, 465].
Apart from the mutations found inmitophagy genes, sev-
eral genes linked to familial Parkinson’s either directly or
indirectly modulate autophagy (including UCHL1, DJ-1,
LRRK2, ATP13A2, USP24, HTRA2, VPS35, SYNJ1, VPS13C,
and GBA) [387, 466], and some of them that are also linked
to and/or regulated by ROS/RNS are discussed below.
5.2.1. UCHL1 (Ubiquitin C-Terminal Hydrolase L1, PARK5).
UCHL1 is a deubiquitylating enzyme [467]. It can impair
autophagosome formation, with the UCHL1 I93M mutant
overriding this suppression [468]. In response to oxidative
stress, UCHL1 promotes cell survival in cancer cells; how-
ever, in rotenone-induced Parkinson’s mouse models,
Kumar et al. reported that UCHL1 undergoes nitrosylation,
disrupting its deubiquitinase activity and causing structural
instability and aggregation, thereby promoting α-syn
aggregation [469, 470].
5.2.2. DJ-1 (Protein Deglycase, PARK7). DJ-1 acts in parallel
with the PINK1/Parkin pathway, playing an important anti-
oxidant role to protect mDANs against oxidative damage
[471]. However, its roles are widespread in the cell (for a
recent review, see [472]). DJ-1 is a cytosolic protein, but
under stress conditions (e.g., oxidative stress), it translocates
to mitochondria and to the nucleus. It contributes to (i)
dopamine production via activation of TH and ADCC; (ii)
regulation of mitochondrial activity via interactions with
the antiapoptotic protein BCL-xL and Complex I; (iii) the
upregulation of CMA, acting as a molecular chaperone inter-
acting with α-syn; and (iv) the regulation of transcriptional
activity via activation of NF-κB, p53, and NRF2 pathways
[308, 472]. Crucially, through NF-κB regulation, DJ-1 con-
trols the expression of mitochondrial uncoupling proteins,
UCP4 and UCP5, that decrease mitochondrial membrane
potential, thereby suppressing ROS production; meanwhile,
DJ-1 binds to Complex I via NDUFA4 to maintain its activ-
ity, and is thus crucial for mDAN survival [472]. As previ-
ously described, DJ-1 is also involved in the nitrosylation of
Parkin1 [311], and DJ-1 itself can be oxidised. This is crucial
for neuroprotection, and indeed, levels of oxidised DJ-1 are
reduced in Parkinson’s patients [307, 473], and low levels of
DJ-1 increase vulnerability to oxidative stress [474].
5.2.3. LRRK2 (Leucine-Rich Repeat Kinase 2, PARK8).
LRRK2 is degraded by CMA, and its most commonmutation
(G2019S) increases its kinase activity, restricting its degrada-
tion [475–477]. G2019S LRRK2 can also inhibit CMA activ-
ity, affecting CMA substrate degradation in general [475,
478]. LRRK2 comprises multiple domains, and thus regulates
several, distinct functions, including neurite outgrowth, vesi-
cle trafficking, nuclear organisation, mitochondrial homeo-
stasis, and autophagy, via different pathways [479]: (i) it
activates endophilin A, a neuron-specific protein involved
in recruitment of ATG3 [118]; (ii) it modulates mitophagy
via Rab10 and Parkin interactions [480, 481]; (iii) it regulates
autophagy by activating ERK, MAPK, and PI3KC3-C1 [482];
and (iv) it modulates lysosomal pH via interactions with the
proton pump [483]. Although yet to be confirmed in mam-
malian cells, yeast wild-type LRRK2 appears able to protect
against oxidative stress, depending on mitochondrial func-
tion and endocytosis, and an increase in dopamine oxidation
has been reported in mutated LRRK2 neurons [484, 485].
Indeed, LRRK2 function may be regulated by ROS, as arse-
nite and H2O2 treatments downregulate LRRK2 phosphory-
lation, preventing binding to 14-3-3 in vitro [486, 487].
Mutations in the lysosomal enzyme, glucocerebrosidase
(GBA)—in which homozygous mutations lead to Gaucher’s
disease—are one of the most common risk factors for Parkin-
son’s, and GBA deficiency is associated with mitochondrial
dysfunction and oxidative stress [488, 489]. In addition, Li
et al. reported in iPSC-derived mDANs from Parkinson’s
patients with mutations in GBA, autophagic and lysosomal
defects, with impaired calcium homeostasis andmitochondrial
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dysfunction in mouse and neuroblastoma cells and increase in
oxidative stress [490].
Finally, as we previously mentioned, glial cells—i.e.,
astrocytes, microglia, and oligodendrocytes—represent about
90% of all cells in the brain, and are critical for maintaining
neuronal homeostasis (e.g., synapse functions, metabolism,
neurodevelopment, myelination, neuroinflammation, and
axonal regeneration) and alterations of neuron-glia signalling
pathways are associated with neurodegenerative diseases,
including Parkinson’s [491–493]. A potential intercellular
regulation of neuronal autophagy by glial cells has been
reported in induced pluripotent stem cell- (iPSC-) derived
motor neurons using conditioned media from iPSC-derived
astrocytes from ALS patients [494]. In addition, overexpres-
sion in astrocytes of the oxidative stress regulator and
autophagy transcription factor NRF2 promotes α-synuclein
degradation in an α-synuclein mutant (A53T) mouse model
[341, 495]. Similarly, di Domenico et al. showed that iPSC-
derived astrocytes derived from Parkinson’s patients pre-
sented deficient CMA, impaired macroautophagy, and α-
syn aggregates, and this was rescued with a CMA activator
[496]. However, the exact mechanism for the regulation of
neuronal autophagy by this pathway remains elusive. On
the other hand, recent studies support a model of direct
transfer of cellular garbage from neurons to glial cells for
their degradation, especially relevant for mitochondria, in a
process termed “transmitophagy” [497]. In this study, dam-
aged mitochondria in the axons of retinal ganglion cells were
engulfed and degraded by neighbouring astrocytes [497]. In
addition, in C. elegans, neurons release vesicles called exo-
phers in a process that is enhanced during stress or when
autophagy is inhibited, and these contain protein aggregates
and organelles that are subsequently engulfed by adjacent
cells [498].
5.3. Parkinson’s Hallmarks Linking Autophagy Disruption
with Increased Oxidative Stress. Certain hallmarks of Parkin-
son’s are thought to exacerbate pathology through the dis-
ruption of autophagic flux. Here, we will describe how
different Parkinson’s features are linked to autophagy disrup-
tion and oxidative stress damage.
5.3.1. Lewy’s Bodies. The best characterised feature of Parkin-
son’s is the presence of Lewy’s bodies; however, these are not
observed in all Parkinson’s cases, and are also found in
healthy patients where they are referred as incidental LB dis-
ease [499]. α-Syn is a major component of this fibrillar aggre-
gate; however, more than 70 additional molecules have been
identified as coconstituents (including DJ-1, PINK1, Parkin
(sulfonylated Parkin leads to protein aggregation and con-
tributes to Lewy’s body formation [298]), and LRRK2)
[500]. Mutations in SNCA (e.g., A53T and A30P), posttrans-
lational modifications (e.g., phosphorylation, ubiquitination,
and oxidation), and autophagy dysfunction increase the rate
of oligomerisation, and thus the formation of inclusions [501,
502]. Importantly, several redox modifications have been
described for α-syn. For example, Giasson et al. reported that
α-syn can be nitrated at specific tyrosine residues, and these
modifications are found in Lewy’s bodies [503]. Jiang and
Chang demonstrated the presence of disulfide bonds in α-
syn that enhance its propensity to aggregate [504]. Ponzini
et al. described that α-syn methionine oxidation inhibits
secondary structure formation [505]. In addition,
mitochondria-associated ER membranes—whose functions
are compromised in Parkinson’s—are also the residence of
a subpopulation of α-syn, and mutations or overexpression
of α-syn enhances the extent of contact sites and affect
mitochondrial function [506–509].
Overall, accumulation of α-syn in oligomers affects neu-
rotransmitter release, synaptic vesicle recycling and traffick-
ing, and autophagy (both CMA and macroautophagy);
meanwhile, it increases ROS/RNS levels (e.g., α-syn oligo-
mers induce Parkin, DJ-1, and UCHL1 nitrosylation), trig-
gers microglial activation, impacts on mitochondrial
homeostasis, and induces ER stress and calcium homeostatic
imbalance [501, 510–518]. In its aggregated form, α-syn can
block CMA, thereby preventing the degradation of itself and
other CMA substrates [513]. Aggregates of α-syn also stimu-
late cell death via oxidative-nitrosative stress, and this
[507]further enhances α-syn persistence leading to a com-
pensatory response of increased macroautophagy and an
accumulation of aggregates in autophagosomes [2]. Con-
versely, α-syn aggregates can also impair macroautophagy
(e.g., the A30P SNCA mutant impairs macroautophagy via
inactivation of c-Jun and activation of the transcriptional
repressor, ZKSCAN3 [515]) [519, 520]. In addition, several
studies have highlighted the presence of different mecha-
nisms for toxic α-syn aggregates to be transferred to other
cells, including via exosomes, direct penetration, endocytosis,
nanotubes, trans-synaptic junctions, or receptor-mediated
internalisation, all of which are predicted to spread pathology
within the brain [510, 521], and indeed, exocytosis and
prion-like intercellular transfer of α-syn increase with
oxidative stress and autophagy impairment [522, 523].
5.3.2. Neuroinflammation. Another Parkinson’s hallmark
that may impact on or be affected by redox imbalance is neu-
roinflammation [524]. Neuroinflammation is an immune
response mainly controlled by microglia and astrocytes in
order to respond to an injury, and remove cell debris, and
triggered in response to toxic molecules. Microglia and astro-
cytes act as antioxidant systems to remove excess ROS/RNS;
however, in Parkinson’s, free radical levels exceed the detox-
ifying capacity, which can be also compromised due to
genetic mutations and autophagy disruption. Oxidative stress
exacerbates this chronic response due to the release of oxi-
dised molecules, including neuromelanin, aminochrone,
and α-syn [525]. In turn, chronic neuroinflammation is
thought to increase oxidative stress by inducing reactive
astrogliosis and microgliosis, leading to the production of
ROS/RNS, and contributing to mDAN death [526, 527]. In
addition, neuroinflammation is also closely related to
autophagy dysfunction. Indeed, TNFα impairs autophagy
flux in microglia, and autophagy induction promotes
microglia polarisation towards a M2 neuroprotective pheno-
type [454]. Similarly, neuroinflammation in premotor neu-
rons in stress-induced hypertension rats blocks autophagy
flux [528], and mitochondrial antiviral signaling (MAVS) in
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microglia is involved in microglial activation and this is neg-
atively regulated by autophagy [529]. In addition, autophagy
regulates the inflammasome—an innate immune system
complex—which in turn inhibits autophagy, and directly reg-
ulates IL-1β signalling [530–532]. Indeed, autophagy-
deficient microglia lead to an increase in inflammasome acti-
vation and causes Parkinson’s-like symptoms in mice [533].
Similarly, autophagy inhibition contributes to the exacer-
bated proinflammatory response in microglia, while autoph-
agy dysfunction in astrocytes might contribute to the
progression of the disease; these are reviewed in detail
elsewhere [534, 535].
5.3.3. Impairment of the UPS. Disrupted protein quality con-
trol in Parkinson’s is linked to impairment of the UPS,
involved in the selective degradation of the majority of
abnormal proteins in the cell [536]. Oxidised and damaged
proteins are mainly degraded by the proteasome and the
autophagy pathway. α-Syn aggregates, mitochondrial dys-
function, oxidative stress, familial Parkinson’s (e.g., Parkin
and UCHL1 mutations correlate with reduction in protea-
some function), and other conditions impair UPS function,
which in turn, leads to an increase in oxidised and damaged
protein levels, increased toxic iron, and increasing vulnera-
bility of mDANs [537–539]. Indeed, in an UPS-impaired
Parkinson’s mouse model, UPS inhibition activated the
autophagy-lysosomal system in mDANs [540]. UPS and
autophagy are closely related and dynamically intercon-
nected, where p62/SQSTM1 appears to be one of the main
modulators [541–543]. In addition, previous evidence
indicates that proteasome function is modulated by redox
modifications [544].
5.3.4. ER Stress. ER stress/dysfunction and chronic UPR acti-
vation are further Parkinson’s hallmarks [545]. Disruptions
in the protein quality control systems and increase in oxida-
tive stress levels contribute to an increase in misfolded pro-
teins in the ER, leading to an exacerbated ER stress and a
chronic UPR activation. When ER stress is too severe, it con-
tributes to the generation of oxidative stress and the UPR ini-
tiates programmed cell death [546]. Consistent with this,
numerous lines of evidence highlight a specific vulnerability
of mDANs to ER stress and protein misfolding [518]. For
example, CHOP depletion in mice has a neuroprotective role
in mDANs against 6-OHDA, but not in a MPTP Parkinson’s
model [547]. Similarly, mDANs deficient of the UPR tran-
scription factor X-box binding protein 1 (XBP1) were resis-
tant to 6-OHDA; however, XBP1 downregulation in the
SNc caused increased neurodegeneration linked to ER stress,
and local SNc XBP1 overexpression had a neuroprotective
effect against 6-OHDA or MPTP [548, 549]. Indeed, similar
results were found with ATF6 overexpression protecting
against MPTP neurodegeneration [550]. MPTP treatment
also affects calcium homeostasis in the ER via inhibition of
the store-operated calcium entry (SOCE) leading to calcium
imbalance [551]. In addition, ER-mitochondria associa-
tions—required for calcium homeostasis, mitochondrial
function, autophagy, and ER functionality [227]—are altered
in Parkinson’s, as is the mitochondrial UPR [507, 552]. Over-
all, the crucial role of ER stress in Parkinson’s pathology sug-
gest a key role of ER-phagy; however, the influence of ER-
phagy in Parkinson’s initiation and progress remains elusive.
5.3.5. Peroxisomal Dysfunction: A New Player? Finally, it is
also important to mention that the other major source of
ROS/RNS in the cell, peroxisomes, are also affected in Par-
kinson’s. Indeed, peroxisomes are required for neuronal
homeostasis and function, and peroxisomal dysfunction has
been suggested to contribute to α-syn aggregation [553–
555]. In addition, recently, Jo et al. identified the mitochon-
drial chaperone HSAP9—associated with Parkinson’s
[556]—acting as a pexophagy regulator in vitro and in vivo;
HSAP9 downregulation in neuroblastoma cells increased
pexophagy activity, and this could not be rescued by HSAP9
mutated forms found in Parkinson’s patients [557]. How-
ever, the precise roles of peroxisomes and pexophagy in
Parkinson’s pathology remain unclear.
Overall, autophagy dysfunction and increased oxidative
stress are two closely related hallmarks present in dopami-
nergic neurons in Parkinson’s, aggravated by other Parkin-
son’s features including mitochondrial dysfunction,
elevated iron and calcium levels, increase in dopamine
oxidation, UPS dysfunction, ER stress, neuroinflammation,
and α-syn aggregation.
6. Overview and Conclusions
Autophagy is an intracellular process required for the main-
tenance of cellular homeostasis, being particularly crucial in
neurons as they are postmitotic cells highly vulnerable to
stress. Dysfunctional autophagy typically correlates with
neurodegenerative diseases, with mitophagy being a particu-
larly important link due to the increased vulnerability of
mDANs to autophagy deficits and mitochondrial dysfunc-
tion [412, 417]. The regulation of autophagy is closely related
to redox homeostasis. To maintain homeostasis, cells have
developed antioxidant mechanisms to control the level of free
radicals in the cell, including the turnover of ROS-damaged
organelles. Upon stress or injury, autophagy is one of the
main antioxidant pathways in the cell via the degradation
of damaged organelles (e.g., degradation of the major source
of free radicals in the cell including mitophagy, ER-phagy,
and pexophagy) as well as damaged/misfolded proteins.
Basal ROS/RNS levels are also important in the cell as they
are involved in cellular signalling, highlighting the beneficial
effect of these radicals for cell survival. Indeed, oxidative
modifications in redox-sensitive amino acids in proteins
involved in the autophagy pathway have been described,
including (i) those involved in the upstream pathway; (ii)
those directly involved in the process, and iii) those involved
with transcriptional regulation of autophagy, highlighting
the interplay between these two processes.
However, when the balance of antioxidant mechanisms
and ROS/RNS generation is disrupted because the antioxi-
dant defence is reduced (e.g., dysfunctional autophagy), or
because ROS generation is increased, oxidative stress is initi-
ated. This can damage the cell, including triggering neuronal
cell death programmes, the primary driver in Parkinson’s. In
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addition, dopaminergic neurons are particularly vulnerable
to autophagy deficits and high levels of oxidative stress. Con-
sistent with this, different factors contribute to the disruption
of the autophagy pathway linked to an increase in oxidative
stress, including (i) dopamine oxidation leading to the for-
mation of the toxic molecules like aminochromone; (ii)
familial Parkinson’s-associated genes involved in autophagy
and oxidative stress regulation; (iii) mitochondrial dysfunc-
tion, including an increase in calcium and iron levels; (iv)
neurotoxins affecting almost exclusively dopaminergic neu-
rons (e.g., MPTP, rotenone); (v) oxidation of biomolecules
(e.g., lipid peroxidation, DNA oxidation, and α-synuclein
oxidation); (vi) UPS dysfunction; (vii) disruption in the cyto-
skeletal transport; (viii) neuroinflammation; (ix) ER stress
and chronic activation of the UPR; and possibly (x) peroxi-
somal dysfunction.
Currently, there are only symptomatic treatments for
Parkinson’s, and no disease-modifying therapies have been
described. The most commonly used approaches to treat
motor deficiencies are based on pharmacological stimula-
tion of the dopaminergic pathway—e.g., levodopa (L-
DOPA, dopamine precursor), dopamine agonists [558],
and nonpharmacological treatments such as deep brain
stimulation (DBS) [559]. However, none of these are capa-
ble of delaying or stopping the progression of the disease.
Other promising therapies, some of them yet not tested in
humans, have been developed over recent years, including
stem cell-based approaches (stem cell and induced plurip-
otent stem cells derived from patients’ fibroblasts have
emerged as a powerful tool to obtain a renewable source
of dopaminergic neurons that can integrate in the brain
[560, 561]), the use of neurotrophic factors (e.g., BDNF
and GDNF (glial-derived neurotrophic factor)), antioxi-
dants as neuroprotective compounds (e.g., NOS inhibitors,
iron chelators, and NRF2 activators [438, 441, 562, 563]),
gene therapy (e.g., viral-gene expression of TH, AADC,
or VMAT2 to induce dopamine release, or NURR1
expression which appears to have a neuroprotective role),
and immunotherapy (e.g., for the clearance of α-synuclein
aggregates) [564–567]. In addition, another divergent
approach is enhancing the autophagy process. The most
tested autophagy enhancers are the mTORC1 inhibitor,
rapamycin, and the inositol monophosphatase inhibitor,
lithium, each of which significantly reduced α-synuclein
aggregates and cell death in Parkinson’s models [568,
569]. However, they are nonselective for autophagy, affect-
ing other pathways, and thus treatment with these com-
pounds presented numerous side effects [570]. For this
reason, recent strategies have focused on specific targeting
of autophagy components (e.g., TFEB and Beclin1) [324,
325, 458, 571–573], or the lysosome, including increased
acidification and overexpression of LAMP2A (targeting
CMA) [459, 571, 574–576].
Overall, there is a strong evidence for the interplay of
autophagy and redox homeostasis and how it plays a crucial
role in Parkinson’s. However, there is still a lot to explore and
future research would contribute to a better understanding of
this tight relationship and potential target for selective
therapies.
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